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 Figure 2.1 Trophoblast invasion in normotensive and preeclamptic placenta. 
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placenta. There is reduced plugging of spiral arteries in preeclamptic 
placentas which remain muscular and vasoconstricted resulting in reduced 
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The structural similarities between FB1 sphinganine (Sa) and sphingosine 
(So) (A) and the consequent inhibition of ceramide synthase (X) in the de 
novo sphingolipid pathway (B) leading to accumulation of sphingoid bases 
and depletion of complex sphingolipids (Schroeder et al., 1994, Wang et 
al., 1999).  
Figure 2.5 The figure depicts the two apoptotic pathways. The extrinsic pathway 
incorporates activation of death receptors and caspase 8 and the intrinsic 
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(mitochondrial) pathway results in apoptosome formation and caspase 9 
activation. Both pathways result in activation of initiator caspases specific 
for the pathway but converge at the level of activation of effector caspases 





A representation of western blot banding pattern for serum samples from 
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Band intensity analysis of sera from preeclamptic and normotensive 
women. * indicates p0.0001. Unpaired T-test with Welch correction, 95% 




A representative HPLC chromatogram from patient‟s serum showing FB1 




Graphical presentation of serum concentrations of FB1 from normotensive 
(n=20) and preeclamptic (n=20) women. FB1 was significantly higher in 
preeclamptics (p=0.03). Two-tailed 95% confidence interval* indicates the 




A representative chromatograph of sphinganine (Sa)/sphingosine (So) 
analysis from serum of pregnant women showing the retention times and 
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peaks for Sa and So. 
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Sphinganine concentrations from normotensive and preeclamptic sera. 
Significantly high concentrations of sphinganine were observed in 
preeclamptics compared to the normotensives. * indicates statistically 
significant difference between the means (p=0.04) using t-test with Welch 
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Malondialdehyde (MDA) concentrations in normotensive and preeclamptic 
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Illustration of molecular interactions of the PAP technique depicting the 




Normotensive placental villi showing numerous capillaries (V) in close 
proximity to the syncytiotrophoblastic cell layer (S), the presence of  
mesenchymal cells (M) and erythrocytes (R) within the intervillous space 
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layer (S) with capillaries is also evident. Cytotrophoblasts (CT) visualised 
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Fumonisin B1 was immunolocalised within the syncytial layer (S) and 
endothelial cells (E). However there was no FB1 within the 
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staining for caspase 3 (Brown staining). Caspase 3 was immunolocalised 
apically in the cytoplasm of syncytiotrophoblasts (S), endothelium (E) and 




Normotensive (A) and preeclamptic (B) villi  showing uniform staining in 
the normotensive sample and an increased number of cells with condensed 
chromatin (arrow) predominantly within the syncytium (S) and also the 





Graphical representation of lipid peroxide levels in normotensive and 
preeclamptic placental tissue samples. The lipid peroxides (MDA) were 
significantly higher (p0.0001) in preeclamptic placental tissues compared 
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Preeclampsia is the leading cause of foetal and maternal mortality and morbidity in 
developing countries. In South Africa, maize is a dietary staple for most black African 
populations and is susceptible to contamination by mycotoxins such as fumonisin B1 
(FB1).Fumonisin B1 is a ubiquitous secondary metabolite of Fusarium fungi produced 
predominantly by Fusarium verticillioides. This mycotoxin shares structural similarities with 
the backbone of sphingoid bases (sphinganine and sphingosine) which are substrates for the 
biosynthesis of complex sphingolipids. The mechanism of FB1 toxicity therefore is centred 
on the disruption of this process. The aim of the present study was to elucidate the possible 
causal link between FB1 and preeclampsia. Following ethical approval, 20 normotensive and 
20 preeclamptic patients were recruited into the study. Blood and placental tissue were 
collected and processed for further analysis. The presence of FB1 was verified using standard 
immunohistochemical and electrophoretic techniques.  The levels of FB1 and sphingolipids 
were quantified using high performance liquid chromatography (HPLC). Western blotting 
was conducted to confirm the presence of FB1 in the serum. Placental tissue apoptosis was 
evaluated using Hoechst staining and other markers. Lipid peroxidation was measured in 
serum and placental tissue of both groups. Fumonisin B1 was immunolocalised within the 
endothelial cells and mesenchymal cells of placentas from both groups, while FB1 was 
present in cytotrophoblastic cells of preeclamptic patients only. In addition, FB1 
concentrations were significantly higher in preeclamptic compared to normotensive serum 
samples. Sphinganine was significantly elevated in preeclamptic serum samples whilst there 
was no statistical difference in the sphingosine levels between the groups. Chromatin 
condensation was higher in the preeclamptic patients. Caspase 3 and Fas were present with 
greater intensity in preeclamptic samples. The levels of lipid peroxidation were significantly 
higher in both serum and placental tissue of preeclamptic patients. This study has 
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demonstrated not only the presence of FB1 in the serum and placental tissues of pregnant 







Hypertensive disorders of pregnancy are the leading cause of maternal and foetal death 
worldwide (Duley, 2005). Preeclampsia is a multi-system disorder unique to human 
pregnancy and is characterised by hypertension and proteinuria in the second half of 
pregnancy (Walker, 2000). Approximately 7-10% of all pregnancies worldwide are affected 
by preeclampsia with incidences as high as 27% in under resourced countries (Walker, 2000, 
Moodley, 1996, Davey and MacGillivray, 1989, Noris et al., 2005). 
 
Although the aetiology of preeclampsia remains obscure, it is widely believed that 
preeclampsia is a trophoblastic disease. Microscopic analysis of placentas from preeclamptic 
women reveals shallow invasion of the spiral arteries by placental trophoblastic cells. This is 
due to an inability to differentiate into invasive trophoblasts leading to vasoconstricted spiral 
arteries and reduced placental perfusion (Robertson et al., 1986, Khong et al., 1986, 
Kaufmann et al., 2003, Kharfi et al., 2003). Cytotrophoblasts are of epithelial origin and in 
order for adequate invasion to occur, they have to differentiate by down-regulating cell 
adhesion molecules of epithelial origin (integrin6/4, E-cadherin) and up-regulate the 
adhesion molecules (VE-cadherin, platelet endothelial adhesion) that are important for 
endothelial cell function (Noris et al., 2005, Robertson et al., 1986, Khong et al., 1986, 
Kharfi et al., 2003, Voss et al., 2002). Thus far the only effective cure for preeclampsia is the 




Oxidative stress is an imbalance between oxidants and antioxidants in the body. The levels of 
oxidative stress are generally high in pregnancy due to the increased energy demands from 
the developing foetus but this process seems to be exaggerated in preeclampsia indicating 
aberrant antioxidant response (Wang and Walsh, 1996, Serdar et al., 2002). Due to the multi-
system involvement in preeclampsia, it is less likely that a single agent will be responsible for 
all the defects observed in this syndrome and highly likely that a variety of factors will work 
together to influence the outcome of the disease.  
 
 The eastern coastline of South Africa is reported to have the highest incidence of 
preeclampsia and approximately 18% of all pregnancies in this area have some form of 
hypertension (Moodley, 1996). Environmental conditions in this geographical region are 
conducive for mould contamination of maize which is the staple diet for most rural 
populations. Contamination of maize by moulds results in the production of mycotoxins most 
of which remain stable under normal cooking conditions and therefore increases the risk of an 
individual‟s exposure to these mycotoxins (Moodley et al., 2001, Chelule et al., 2001). 
Fumonisin B1is a mycotoxin produced by the mould Fusarium verticillioides that has been 
implicated in numerous animal diseases such as porcine pulmonary oedema, equine 
leukoencephalomalacia and hepatocarcinoma in rats (Voss et al., 2002, Harrison et al., 1990, 
Ross et al., 1991, Gelderblom et al., 2001). In addition, it has been implicated as an 
aetiological agent in oesophageal cancer in humans in China and South Africa (Yoshizawa et 
al., 1994, Chu and Li, 1994, Sydenham et al., 1990). Fumonisin B1 contains a hydrocarbon 
backbone similar to that of sphingoid bases (sphinganine (Sa) and sphingosine (So)), a 
terminal amino group and several tricarballylic acid moieties. The mechanism of FB1 toxicity 
is postulated to be through the inhibition of ceramide synthase, a key enzyme in de novo 
sphingolipid metabolism which requires the sphingoid bases as substrates (Merrill et al., 
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1997, Riley et al., 1996, Merrill  et al., 1996). The tricarballylic acid moieties bind to the 
fatty acid binding domain while the amino group binds on the sphingolipid-binding domain 
of the enzyme. Through this interaction the enzyme functions are obliterated by FB1 and 
consequent to this is the depletion of complex sphingolipids (ceramides, sphingomyelin) and 
elevation in sphingoid bases. Furthermore, there is also increased DNA fragmentation, 
decreased cell viability, loss of regulation of differentiation and apoptotic morphology 
associated with FB1 toxicity (Chu and Li, 1994, Sydenham et al., 1990, Merrill et al., 1996). 
The ratio of Sa/So has been used as a biomarker in animal and in vitro models but most 
studies have not produced significant results especially in human samples (van der 
Westhuizen et al., 1999, Tran et al., 2003, Cano-Sancho et al., 2011). More recently, urinary 
FB1 has been proposed as a reliable biomarker of exposure in rural populations (van der 



















The purpose of this study was to: 
 Determine the presence of and quantify FB1 in the blood and placental tissues of 
pregnant women 
 Quantify the levels of Sa and So as possible biomarkers for FB1 exposure in 
pregnancy 
 Compare the levels of apoptosis between the pregnancies complicated by 
preeclampsia and the normotensive pregnancies 
 Measure lipid peroxidation as indicated by the levels of malondialdehyde in serum 




















2.1 Hypertensive disorders of pregnancy 
 
Hypertension is the leading cause of mortality and morbidity associated with pregnancy 
(Walker, 2000). The prevalence of these disorders varies between countries with the highest 
burden reported in developing countries.   At King Edward VIII Hospital (KEH), Durban, 
South Africa, 18% of all admissions to the obstetric unit have some degree of hypertension 
(Moodley, 1996).The prevalence in Zimbabwe is 7.1% while 6-8% of all pregnancies in the 
United States are affected by some form of hypertension (Wacker et al., 1998). The mortality 
rates from preeclampsia and eclampsia are also generally higher in developing countries 
compared to developed countries (Wacker et al., 1998, Subramaniam, 2007). According to 
the South African National Committee on Confidential Enquiries into Maternal Deaths 
(NCCEMD), KwaZulu-Natal (KZN) Province has the highest maternal mortality rates in 
South Africa and of all complications of pregnancy hypertension is the leading cause of 
maternal death nationwide (NCCEMD, 2000). The high mortality rates reported in KZN may 
also be due to effective reporting systems in this province‟s health departments and may not 
be a true representative of the national situation. Interestingly, the NCCEMD also reported 
the highest mortality rates in black women compared to other races in South Africa. Various 
factors may contribute to these discrepancies including the inaccessibility of the antenatal 
care for rural black women, the lack of proper infrastructure and low socio-economic and 
nutritional status of these women (Okafor and Aniebue, 2004, Wacker et al., 1998, Chelule et 
al., 2001). Climatic conditions such as high temperatures and humidity have also been 




2.1.1 Classification of hypertensive disorders of pregnancy 
The American College of Obstetricians and Gynaecologists and more recently the national 
high blood pressure education program working group on high blood pressure (NHBPEP)   in 
Pregnancy have classified hypertension in pregnancy into four categories as follows 1) 
gestational hypertension, 2) chronic hypertension, 3) preeclampsia superimposed on chronic 
hypertension and 4) preeclampsia. The term pregnancy induced hypertension (PIH) has 
recently been removed from the classification as it is believed to be misleading (Leeman and 
Fontaine, 2008, Peters and Flack, 2003, Marik, 2009, Duley, 2005). 
 
Gestational hypertension was previously known as PIH and is characterised by development 
of hypertension without proteinuria after the twentieth week of gestation in a previously 
normotensive individual with no history of hypertension. It is an interim diagnosis reserved 
for women who are eventually diagnosed with preeclampsia or chronic hypertension. Half of 
the women diagnosed with gestational hypertension between 24 and 35 weeks develop 
preeclampsia. Severe gestational hypertension is associated with poor perinatal outcomes 
compared to women with mild preeclampsia and management is similar to the one used in 
severe preeclampsia (Leeman and Fontaine, 2008, Peters and Flack, 2003, Marik, 2009, 
Duley, 2005). 
 
Chronic hypertension is characterised by blood pressure measurement of 140/90 or higher, 
taken on two occasions before the 20
th
 week of gestation and continuing beyond 12 weeks 
following delivery. Superimposed preeclampsia is the primary contributor to morbidity 
observed in chronic hypertension and usually results from sudden increase in blood pressure 
and new proteinuria. Treatment of mild to moderate chronic hypertension however seems to 
be unhelpful in preventing preeclampsia or of any benefit to the foetus. Excessive decrease in 
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blood pressure through the use of antihypertensive medications may also result in reduction 
in placental perfusion which will further impact on foetal development. However, treatment 
is warranted when the patient‟s BP persists above 150mmHg/110mmHg to prevent end-organ 
damage (Leeman et al., 2008; Peters and Flack, 2004; Marik, 2009; Duley, 2003). 
 
Preeclampsia superimposed on chronic hypertension is encountered in women with chronic 
hypertension who develop new signs or symptoms of preeclampsia in the second half of 
pregnancy. These signs include a raised blood pressure and new proteinuria (Sibai et al., 
2005, Leeman and Fontaine, 2008, Peters and Flack, 2003, Marik, 2009, Duley, 2005). 
 
Preeclampsia is a multisystem disorder unique to human pregnancy with an unexplained 
aetiology. It is characterised by an abnormal response of the vasculature to placentation. The 
diagnosis is based on the high blood pressure of 140/90 mmHg taken on two occasions 6-
hours apart and proteinuria of 300mg in a  24 hour-urine specimen after twenty weeks of 
gestation.Proteinuria is usually determined by means of Dipstix (Table 2.1), which gives 
semi-quantitative measurements. False positives result if the urine is too concentrated or 
contaminated, while grossly diluted urine gives false negatives (Sibai et al., 2005). 
 
Table 2.1: Approximate protein concentrations in urine as determined by Dipstix (Ames) 
Redrawn from (Moodley, 1996) 
Dipstix ® result Approximate 
concentrations  
Trace 0.1g/l    







Proteinuric hypertension is the most widely accepted definition of preeclampsia while 
oedema is now omitted from all definitions of preeclampsia. Preeclampsia is also known to 
affect multiple systems with varying severity depending on the system affected. The central 
nervous system complications include convulsions (eclamptic), cerebral and retinal oedema, 
and cortical blindness while necrosis of the renal cortex and tubules is the most common 
manifestation of renal involvement. Pulmonary oedema, jaundice, hepatic infarction and the 
haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome are also most 
commonly encountered in preeclampsia. Preeclamptic placentas are prone to infarction, 
uteroplacental bleeding and abruptio placentas (deSwiet, 1995, Sibai et al., 2005). 
 
 While the aetiology remains elusive, abnormal placentation is the major cause of this 
disease. Abnormal placentation is characterised by the inability of cytotrophoblastic cells to 
invade maternal spiral arteries resulting in vasoconstricted vessels with reduced delivery of 
blood and nutrients to the placenta (Lyall et al., 2001, Jauniaux et al., 2006). The failure of 
invasive cytotrophoblasts to mimic the endothelial system by increasing expression of 
adhesion molecules of endothelial origin (VE-cadherin, vascular endothelial adhesion 
molecule-1) and down-regulation of adhesion molecules from their epithelial phenotype (E-
cadherin, integrin 6) is the major cause of this shallow invasion observed in preeclampsia 
(Kharfi et al., 2003).  
 
Routine nutritional supplementation in an attempt to prevent preeclampsia proved 
unsuccessful whilst calcium supplementation resulted in decreased risk of developing 
preeclampsia in high risk women. Low dose aspirin is also effective for use in women at 
increased risk of preeclampsia. Hydralazine has been used for treatment of preeclampsia for 
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many decades but due to undesirable side effects has been discontinued (Leeman and 
Fontaine, 2008, Peters and Flack, 2003, Marik, 2009, Duley, 2005, Walker, 2000). 
 
2.2 The placental development and preeclampsia 
Mammalian placental tissue is an important organ required for maternal and foetal exchange 
of nutrients and gases (Hole, 1987, Tarrade et al., 2001). With an inherent endocrine 
capability, this organ ensures an optimum supply of hormones required during gestation such 
as the human chorionic gonadotropin and human placental lactogen. In addition to this, the 
placental growth hormone which appears in the maternal blood from 12 to 20 weeks up to 
term regulates the maternal blood glucose and supply of nutrients to the placenta. Although 
its function is poorly understood, human chorionic somatomammotropin production is also 
gradually increased during pregnancy (Evain-Brion and Malassine, 2003, Tarrade et al., 
2001).  
 
The prenatal period of development consists of a cleavage stage and begins with fertilisation 
in the uterine tube. Following fertilisation and formation of a zygote, two daughter cells are 
formed during mitosis and after a series of divisions form a hollow ball of cells called the 
blastocyst. These blastocysts eventually become the trophoblasts that release proteolytic 
enzymes (matrix metalloprotease-9) to digest a portion of the endometrium and sink slowly 
into the depression. The cells of the trophoblast begin to produce tiny, finger-like projections 
(microvilli) that grow into the endometrium to complete the cleavage period (Hole, 1987).  
 
During a normal pregnancy, after implantation of the embryo the foetal trophoblastic tissue 
migrates in two phases down the spiral arteries (Figure 2.1), displacing the musculo-elastic 
structure of these arteries (Robertson et al., 1986, Kaufmann et al., 2003, Lyall et al., 2001, 
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Jauniaux et al., 2006). The first phase affects the decidual portions (8-10 weeks) and the 
second phase affects the myometrial portions (16-18 weeks) of the arteries resulting in 
dilatation.This physiological transformation is characterised by a gradual loss of the normal 
musculo-elastic structure of the arterial wall and replacement by amorphous fibrinoid 
material in which trophoblast cells are embedded. These physiological changes are necessary 
for a successful pregnancy and ensure a continuous supply of oxygen and nutrients from the 
maternal blood (Lyall et al., 2001, Kaufmann et al., 2003, Jauniaux et al., 2006). 
 
2.2.1 Pathogenesis and aetiology of preeclampsia 
In preeclampsia the second phase of trophoblastic invasion described above fails to occur and 
the myometrial portions of the spiral arteries remain muscular and undilated with a 
propensity towards vasoconstriction. This makes defective trophoblast invasion the main 
consistent histological feature in preeclampsia (Kaufmann et al., 2003, Lyall et al., 2001, 
Robertson et al., 1975, Jauniaux et al., 2006). Figure 2.1 represents the features that are 
observed in normal and preeclamptic trophoblast invasion. The cytotrophoblastic cells are the 
chief participants in this process and behave like pluripotent stem cells where they 
differentiate into 3 main types of cells important for placental development, the anchoring 
trophoblasts, the villous cytotrophoblasts and the extra villous (invasive) trophoblasts.  
 
The villous trophoblasts are responsible for the endocrine properties of the placenta whilst the 
anchoring trophoblasts are important for attachment of the placenta to the uterine wall and 
thus express adhesion molecules important for this function. The invasive trophoblasts are 
responsible for the morphological changes observed in spiral arteries during pregnancy. A 
differentiation of cytotrophoblasts into invasive trophoblasts is achieved through loss of their 
epithelial phenotype and acquisition of an endothelial phenotype through increased 
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expression of vascular adhesion molecules (VE-cadherin, platelet endothelial adhesion 
molecule, vascular endothelial adhesion molecule 1 and 4-integrins) and down-regulation of 
epithelial adhesion molecules such as integrin 6/4, v/5, E-cadherin (Khong et al., 1986, 
Zhou et al., 1997). This hypothesis has however been challenged by studies that 
demonstrated that the adhesion molecules may not be entirely responsible for the aberrant 
invasion observed. Nonetheless, these changes are not evident in placentas from preeclamptic 
pregnancies (Zhou et al., 1997, Kharfi et al., 2003).  
 
 
Figure 2.1: Trophoblast invasion in normotensive and preeclamptic placenta. Normotensive 
pregnancies show increased plugging of spiral arteries by invasive cytotrophoblasts, thus 
allowing adequate blood supply to the placenta. There is reduced plugging of spiral arteries in 
preeclamptic placentas which remain muscular and vasoconstricted resulting in reduced 
uteroplacental perfusion (Jauniaux et al., 2006). 
 
Despite the extensive research conducted in preeclampsia no single agent can be implicated 
in the syndrome. It is believed that the aetiology lies in the interaction between genetic, 
environmental and immunologic factors (Figure 2.2). Various genes have been surveyed for 
their possible involvement in preeclampsia including endothelial nitric oxide synthase 
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(eNOS), angiotensinogen, human leukocyte antigen-G, endothelin epoxide hydrolase and 
glutathione S-transferase (GST). However, none of the studies have successfully produced 
unequivocal evidence of the gene‟s aetiological role in preeclampsia (Moses et al., 2000, 
Masse et al., 2002, Guo et al., 1999, Williams and Broughton Pipkin, 2011, Zhang et al., 
2008). The genetic studies have also been limited by the fact that preeclampsia is unique to 
pregnancy and resolves following delivery and therefore does not provide an opportunity to 
study after pregnancy. 
 
Figure 2.2: Schematic representation of the proposed involvement of placental molecular 
mechanisms in pathogenesis of preeclampsia adapted from (Kharfi et al., 2003). 
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The foeto-placental unit serves as an allograft because it contains paternal antigenic tissue 
that is foreign to the maternal host. A normal pregnancy represents a state of immune 
adaptation but the immune response in preeclamptic pregnancies is exaggerated (Dekker and 
van Geijn, 1996 , Southcombe et al., 2011, Sibai et al., 2005). Immune maladaptation and 
subsequent activation of decidual lymphoid cells lead to an increase in trophoblastic cell 
derived lipid peroxides in preeclampsia. These placental lipid peroxides may increase 
secretion of thromboxane and cause progressive vasoconstriction in the placental vasculature. 
During an immune response and/or prolonged period of ischaemia activated neutrophils 
undergo a „respiratory burst‟ causing production of superoxide (O2

) and hydrogen peroxide 
(H2O2). These free radicals destroy the integrity of endothelial cells, vascular basement 
membrane and sub-endothelial matrix which consequently results in endothelial dysfunction, 
a feature that is also characteristic of preeclampsia (Dekker and Sibai, 1998). 
 
A plethora of growth factors/cytokines or their receptors studied during trophoblast invasion 
revealed their importance in placental development. Epidermal growth factor is a major 
regulator of the implantation process as it plays a role in the invasion, differentiation and 
proliferation of trophoblasts (Staun-Ram and Shalev, 2005). High levels of tumour necrosis 
factor (TNF)- have been implicated in the induction of apoptosis in cytotrophoblasts and 
therefore is important in the maintenance of cellular homeostasis during placental 
development. It also enhances formation of endothelial cell molecules like endothelin whilst 
decreasing acetylcholine-mediated vasodilation. Prior to the development of preeclampsia, it 
is reported that serum levels of TNF- and its soluble receptor are elevated (Sibai et al., 
2009, Hunt et al., 1996). Interleukin (IL)-6 and leukaemia inhibitory factor are important in 
implantation (Robb et al., 2002). Other cytokines important during trophoblast differentiation 
include epidermal growth factor, insulin-like growth factor-II and IL-1 which positively 
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regulate differentiation of trophoblasts along the invasive pathway. Transforming growth 
factor (TGF)- is a known inhibitor of migration and proliferation of extravillous 
trophoblasts and its serum concentrations are significantly higher in preeclamptic pregnancies 
than in normotensive pregnancies (Naicker et al., 2002, Benyo et al., 2001, Staun-Ram and 
Shalev, 2005). 
 
Other risk factors such as nulliparity, limited sperm exposure and the extremes of age of first 
pregnancy are also associated with a high risk of developing preeclampsia. Subsequent 
pregnancies reduce the risk significantly except where there is a history of hypertension in 
previous pregnancies (Sibai et al., 2005). In addition, pregnant women who attended 
antenatal care have a lower risk of developing preeclampsia compared to those with no 
antenatal care (Ansari et al., 1995). Access to antenatal care in most developing countries is 
still a luxury and thus this may explain the high incidence of preeclampsia in developing 
countries.  
 
Angiogenic imbalance may also play role in the pathogenesis of preeclampsia. There is up-
regulation of anti-angiogenic factors such as soluble fms-like tyrosine kinase -1(sFlt-1) along 
with a reduction in the pro-angiogenic factors (vascular endothelial growth factor (VEGF) 
and placental growth factor (PGF) in preelamptic placentas. sFlt-1 inhibits the pro-angiogenic 
factors, VEGF and PGF by interfering with their interaction with at the receptor level. The 
levels of sFlt-1 are reportedly high in preeclamptic pregnancies compared to their 
normotensive counterparts (Wolf et al., 2005, Maynard et al., 2003, Ferrara, 2001). 
 
In addition to smoking, nutritional status and climatic conditions may also play a role in 
preeclampsia. Rural African communities are heavily reliant on maize as their staple and 
15 
 
numerous studies have demonstrated the contamination of maize by various species of 
moulds including Fusaria (Haschek et al., 1992, Wilkes and Sutherland, 1998, Musser  and 
Plattner, 1997). A consequence to this contamination is the exposure of the individuals to the 
mycotoxins produced by these moulds. Moodley et al. reported the highest levels of 
preeclampsia in the Eastern coastline of South Africa and postulated that this may be 
attributed to the dietary staple for this population being maize (Moodley et al., 2001). 
 
2.3  Fumonisins 
Fumonisins are a group of naturally occurring mycotoxins produced by moulds of the 
Fusarium species. These mycotoxins were originally isolated from Fusarium moniliforme 
(recently named F. verticillioides) MRC 826 by the Programme on Mycotoxins and 
Experimental Carcinogenesis (PROMEC) group of South African researchers (Bezuidenhout 
et al., 1988, Gelderblom et al., 1988). Fusarium proliferatum and F. nygamai cultures were 
also shown to produce fumonisin (Thiel et al., 1991).The fumonisin isolated from the maize 
cultures in Transkei was designated fumonisin B1 (FB1) (Haschek et al., 1992). Since then, 
over 28 types of fumonisins have been discovered and it is very likely that the list will grow 
even further as more fumonisins are discovered. The major fumonisin isolated from the 
Fusaria cultures include B1, B2, B3, B4, A1, A2, C1 and the P (FP1-3) (Wilkes and Sutherland, 
1998, Musser  and Plattner, 1997).  
 
2.3.1 Structure of fumonisins 
Fumonisin B1 is the most toxicologically significant and most abundantly produced 
fumonisin. The backbone of the B series is 2-amino-12,16, dimethyl-3,5,10,14,15-
pentahydroxyicosane joined in diester linkage with propane-1,2,3-tricaboxylic acid 
(tricarballylic acid (TCA)) via hydroxyl groups at C-14 and C-15; and the terminal carboxyl 
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group of TCA. In addition to FB1, FB2, FB3 and FB4 are also found in naturally contaminated 
foods and differ structurally in the number and position of hydroxyl groups on their 
hydrocarbon chain (Figure 2.3). The free amino group on the B series distinguishes them 
from the A series (FA1 and FA2), which are the N-acetyl derivatives. Fumonisin C1 also 
differs from FB1 in that it lacks the amino-end terminal-methyl group. In the P series, 3-
hydroxypyridinium replaces the amine at C-2 and can occur in amounts approximately one-
third of the B-series (Bezuidenhout et al., 1988, Gelderblom et al., 1988) (Figure 2.4) .The 





Fumonisin R2 R3 R4 Fumonisin R2 R3 R4 
B1 OH OH H B4 H H H 
B2 H OH H A1 OH OH CH2CO 
B3 OH H H A2 H OH CH2CO 
 
 
Figure 2.4: The hydrocarbon backbone of fumonisins showing the position of TCA side 
chains, amino and hydroxyl groups. Differences in the position and number of hydroxyl 
groups and the acetylation of the amino group are depicted, redrawn from Norred, 1993.  
 
The tricarballylic acid moieties and amide groups on the FB1backboneare important in its 














production of tortillas resulted in cleavage of the TCA groups on FB1and yielded less toxic 
hydrolysed fumonisins with low biological activity (Palencia et al., 2003). Furthermore, 
acetylation of the primary amino groups also resulted in reduction in toxicity (Gelderblom et 
al., 1993). Norred demonstrated that both FB1 and FB2 were poorly absorbed from the 
gastrointestinal tract and rapidly cleared from the blood. Although very little accumulates in 
the tissues, the liver and the kidney have been shown as reservoirs for FB1 in the body 
(Norred, 1993). Interestingly the kidney was shown to have significantly higher 
concentrations of FB1 than the liver (Riley and Voss, 2006). Fumonisin B1 is also 






C) encountered during the cooking 
or processing of maize making it difficult to decrease its toxicity (Dupuy et al., 1993, Alberts 
et al., 1990). Fermentation of maize to ethanol also resulted in very little degradation of FB1 
whilst it was not recovered in distilled alcohol (Bothast et al., 1992).   
 
2.3.2 Occurrence of fumonisins in foods and feed 
One hundred countries have implemented legislation on the regulation of the amount of 
mycotoxins allowed in food for human consumption. Only 15% of these countries are 
African and there is huge variation between countries on the maximum level of mycotoxins 
allowed in food. The United States recommends the maximum amount of aflatoxin in food to 
be 20g/kg with the exception of milk while the European Union is by far the strictest with 
only 4g/kg total aflatoxin allowed. Rural African communities are at a much higher risk of 
exposure to mycotoxins due to their dependence on subsistence farming of maize (Wagacha 
and Muthomi, 2008, Wagacha et al., 2012, Shephard et al., 2007).  The Eastern Cape 
province of South Africa has been the hub of mycotoxin research and is the area where high 
levels of fumonisins were discovered. There is also a high incidence of oesophageal cancer in 
this area (Shephard et al., 2007). A study by Thiel et al. showed that maize in this region had 
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the highest FB1 concentrations produced mainly by the F. verticillioides (Thiel et al., 
1991).Burger et al. also reported a huge variation in the amount of fumonisin between home-
grown maize and commercial maize in the Transkei (Burger et al., 2010).Maize samples from 
rural areas in KZN contained significantly higher concentrations of FB1 compared to their 
urban counterparts (Chelule et al., 2001).  
 
Mycotoxin production can occur during harvest, storage and food processing (Wagacha and 
Muthomi, 2008). Environmental conditions such as humidity, temperature below 22
0
C and 
frequent rain during the first 2 weeks after silking contribute to production of mycotoxins by 
moulds infecting the maize (Chelule et al., 2001). Therefore, depending on climatic 
conditions some areas around the world would have high concentrations of mycotoxins 
compared to others. In addition to climatic conditions, processing of maize-based products 
either commercially or domestically also affects the amount of mycotoxins produced. For 
example,  nixtamalisation of maize to make tortillas results in decreased concentration of FB1 
while fermentation of maize to ethanol and high temperature (100
0
C) have very little effect 
on the production of FB1 by the moulds.  
 
Analysis of food samples in Zimbabwe showed high concentrations of FB1 and F. 
verticillioides concentrations were higher in maize, wheat, sorghum and rapoko (finger 
millet) compared to nuts (Gamanya and Sibanda,2001).In Ghana the predominant fungal 
contaminant is Aspergillus spp. (65%) which co-occurs with Furarium spp. (5.1%).Co-
occurrence of fumonisins with other mycotoxins was also demonstrated in cereal and spice 
from Morocco (Zinedine et al., 2006). In the Kenyan Kisii district, the highest concentration 




The People‟s Republic of China (Shangqui, Cixian&Linxian Counties) reported co-
occurrence of FB1 (48%), trichothecenes (A and B) and aflatoxin B1 (AFB1) in the high risk 
areas for oesophageal cancer while only 25% of FB1 was reported in the low risk area (Chu 
and Li, 1994, Yoshizawa et al., 1994). Maize imported into Thailand from the USA 
contained less FB1 than that imported from Australia. By far maize samples from the UK 
were the safest with regard to mycotoxin production (Patel et al., 1997).Comparison of 
fumonisin levels in rice and corn from Argentina revealed that corn flour contained higher 
levels of FB1 compared to rice (Lerda et al., 2005). In India, FB1 was found in rain-affected 
maize and sorghum samples and only a few in poultry feed samples (Shetty and Bhat, 1997A, 
Shetty and Bhat, 1997B). All these studies together demonstrate the ubiquitous nature of 
these mycotoxins and the potential risk they pose to human and animal health. 
 
2.3.3 Toxic effects of fumonisins in animals 
Male BD IX rats fed with freeze- or oven-dried culture material of F. moniliforme MRC 
826developed hepatocellular and ductular liver carcinomas. Purified FB1 caused marked 
reduction in weight gain, induction of -glutamyltransferase (GGT)-positive foci and toxic 
hepatitis. In addition, liver function enzymes such as alanine transaminase (ALT), aspartate 
transaminase (AST) and alkaline phosphatase (ALP) were increased. Feeding various 
concentrations of FB1 to rats and mice showed significant interspecies differences as mice 
showed mild hepatic injury while rats showed minimal mild nephrosis, demonstrating that 
mice were less sensitive to FB1 than rats (Voss et al., 1996). Other effects of fumonisin in rats 
include decreased food intake and body weight gain, decreased organ weights (absolute/ 
relative), increased sphinganine (Sa) and sphingosine (So) ratio in urine, serum, liver and 




Equine leukoencephalomalacia (ELEM), a disease that is characterised by liquefactive 
necrosis of white matter in one or both cerebral hemispheres was associated with 
consumption of mouldy maize contaminated with F. verticillioides (Meireless et al., 1994). 
Fumonisin B1 was implicated as the causative agent of ELEM by Marasas et al in 1988; the 
study showed that dosing two horses with culture material of F.moniliforme MRC 826 caused 
brain oedema and hepatosis (Marasas et al., 1988). Injection of extracted and purified FB1 
into a horse caused symptoms typical of ELEM such as apathy, nervousness, a wide-based 
staring stance, shuffling gait, incoordination and bumping into objects, trembling, ataxia, 
reluctance to move, paresis of the lower lip and tongue, inability to eat and drink with 
principal lesions being severe oedema of the brain and focal necrosis in the medulla 
oblongata (Wilkins et al., 1994). 
 
In pigs, consumption of feed contaminated with fumonisins caused symptoms of porcine 
pulmonary oedema (PPE) such as acute onset of dyspnoea, lethargy, weakness, increased 
respiratory rate, cyanosis and death, concurrent hydrothorax and pulmonary oedema. The risk 
of PPE increased as the concentration of fumonisins increased. Intravenous injection or 
feeding of pigs with FB1 caused decreased feed consumption, increased total bilirubin, 
cholesterol and liver enzymes (GGT, ALP, ALT, AST, arginase), mild to severe respiratory 
distress and interstitial pulmonary oedema with increased respiration rate and marked 
cyanosis.  Other hepatic changes include disorganisation and necrosis of hepatocytes, loss of 
sinusoidal microvilli, pancreatic acinar cell degradation and the presence of membranous 
material in hepatic sinusoids and pulmonary intravascular macrophages. Increased free Sa 
and Sa/So ratio in the liver, lung and kidney before histopathological or serum biochemistry 




Poultry are less susceptible to toxic effects of fumonisins than other animals. However, 
diarrhoea, significant decreases in body weight and average daily grain (or feed) conversion 
were noted. In addition, increases in relative weights of liver, kidney, gizzard and 
proventriculus were observed in day-old broiler chicks fed diets containing FB1for 14 to 21 
days. Biliary hyperplasia, multifactorial hepatic necrosis, muscle necrosis, intestinal goblet 
cell hyperplasia and rickets also occurred (Espada et al., 1994, Wiebking et al., 1993).  
 
Baboons fed with culture material of F. verticillioides developed acute congestive heart 
failure and hepatic cirrhosis (Kriek et al., 1981) while vervet monkeys developed hepatitis 
(Jaskiewicz et al., 1987). A low fat diet with added fumonisins caused the development of an 
atherogenic profile, i.e. increased cholesterol, low density lipoprotein (LDL)-cholesterol, 
apoprotein B, liver enzymes, albumin, factor VII and fibrinogen which are possibly due to 
chronic liver toxicity (Fincham et al., 1992).  
 
In cattle, consumption of a fumonisin-contaminated diet for thirty days resulted in cattle 
showing signs of hepatobiliary changes (i.e. increased cholesterol, bilirubin and enzymes) but 
no observable change in feed intake, body weight or temperature. They were however 
languid, visibly distressed and ate their food sluggishly (Osweiler et al., 1993, Smith and 
Thakur, 1996). Rabbits fed with fumonisin-contaminated diet developed central nervous 
system changes similar to ELEM and a dose of 1.75mg/kg/day diet resulted in liquefaction 
and haemorrhage in the brains of pregnant rabbits, hepatic and renal changes (predominantly 
apoptosis) were also observed (Bucci et al., 1996). Hepatic and nephrotoxicities were also 





2.3.4 Effects of FB1 in humans 
High incidence of neural tube defects (NTD) have been reported in  Africa, China and Texas 
causing health authorities to question a possible relationship between consumption of maize 
products and a cluster of NTDs  in these regions (Missmer et al., 2006, Marasas et al., 2004). 
In Texas, the increased risk of NTDs was related to the amount of tortillas consumed as well 
as the source (Missmer et al., 2006). Women who consumed home-made tortillas had a 
higher risk of NTD compared to those who purchased their tortillas. Neural tube defects are 
often associated with a deficiency in folic acid and the mechanism by which FB1may induce 
NTDs is postulated to be via the disruption of sphingolipid metabolism (Collins et al., 1998).  
Folate transporters are phosphatidylinositol anchored proteins and components of lipid rafts 
which are rich in cholesterol and sphingolipids. Therefore a disruption of sphingolipid 
metabolism by FB1 results in decreased entry of the folate into the cell due to a decrease in 
receptors was demonstrated in various cell lines treated with FB1 (Stevens and Tang, 1997, 
Marasas et al., 2004).  
 
Maize and maize based products are staple foods for most rural black populations of Southern 
Africa.  The high risk of oesophageal cancer (OC) has been associated with consumption of 
mycotoxin-infected maize or maize based products (Rava et al., 1996). Common contributing 
factors in the high incidence regions of OC include mineral poor soil with excessive 
alkalinity and low annual rainfall, resulting in stressed plants susceptible to heavy fungal 
contamination (e.g. F. verticillioides). 
 
A strong link between OC and fumonisins was discovered by the PROMEC group studying 
low (Bizana and Lusikisiki) and high (Butterworth and Kentani) risk OC areas in the 
Transkei. During 1985 and 1986, cytological examinations were done on adults in the low, 
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intermediate and high OC rate areas from 12 households (Rheeder et al., 1992). Mild and 
advanced cellular changes occurred more frequently in the high OC rate household 
occupants. In households whose members showed cytological abnormalities, both good and 
mouldy home-grown maize showed significantly higher prevalence of F. verticillioides. 
Furthermore, the healthy maize samples from the high OC incident areas had significantly 
higher levels of FB1 and FB2 compared with the low OC rate areas (Rheeder et al., 
1992).Yoshizawa et al. have also reported higher incidence of maize contamination with 
fumonisins in maize from the high OC risk area compared with the low risk areas in China 
(Yoshizawa et al., 1994).  
 
2.3.5 Mechanism of action of fumonisin B1 
Fumonisin B1 is a structural analogue of sphingoid bases (Figure 2.4A), Sa and So and thus 
acts as a substrate for the enzyme ceramide synthase (sphingosine N-acyltransferase) 
important in the de novo sphingolipid biosynthesis (Figure 2.4B). As a result of this 
similarity, the sphingolipid-binding domain of the enzyme recognises the primary amino 
group on FB1 while the tricarballylic acid moieties are recognised by the fatty acyl binding 
domain of the enzyme  resulting in inhibition (Riley et al., 2001).Fumonisins lacking the 
tricarballylic acid groups (partially hydrolysed) showed low biological activity and toxicity 
compared to unhydrolysed FB1. The acetylation or methylation of the amide groups on 
FB1was also unable to elicit any toxic effects in both in vivo and in vitro studies (Howard et 
al., 2002, Norred et al., 2001). 
 
Although sphingolipids are available from the diet, the de novo pathway of sphingolipid 
synthesis plays a pivotal role in supplying the body with the complex lipids (Riley et al., 
2001). The de novo sphingolipid pathway begins with the condensation of palmitoyl-CoA 
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and L-serine to form 3-ketosphinganine (catalysed by serine palmitoyltransferase; SPT). Due 
to the inability to detect the 3-ketosphinganine derivative in vivo, the reduction of 3 
Ketosphinganine (3-ketosphinganine reductase) to sphinganine is rapid. Acylation of the 
amino group on the sphingoid bases results in formation of dihydroceramides (catalysed by 
ceramide synthase). Additionally other O-acylated, phosphorylated and N-methylated 
derivatives also exist. Finally, the formation of ceramide that is catalysed by desaturase 
results in the insertion of a 4, 5-trans double bond into sphingoid base backbone.  
 
Ceramide synthase is a target for mycotoxins such as FB1, Alternaria toxin, Australifungins 
and N-acylaminopentols. The increase in sphingoid bases observed following FB1 exposure 
results when the capacity of sphingosine kinase to degrade sphingosine to its 1-phosphate 
derivative has been exceeded (Soriano et al., 2005, Riley et al., 2001). In the absence of an 
exogenous sphingoid base source, loss of this pathway by mutation on SPT or its metabolites 
affects growth and viability. Therefore through inhibition of this pathway FB1 may indirectly 
affect the processes dependent on these molecules (van der Westhuizen et al., 2001a, Desai et 







Figure 2.4: The structural similarities between FB1sphinganine (Sa) and sphingosine(So) (A) 
and the consequent inhibition of ceramide synthase (X) in the de novo sphingolipid pathway 
(B) leading to accumulation of sphingoid bases and depletion of complex sphingolipids 










Sphingolipids are ubiquitous cellular membrane components and mediators of cellular 
communication especially in the brain tissue and nerve cells. They contain a sphingosine 
backbone instead of glycerol, two alcohols and an amino group. These sphingolipids are 
precursors of important complex sphingolipids such as ceramide and sphingomyelin which is 
a component of the myelin sheath (Soriano et al., 2005). The levels of sphingolipid 
metabolites are tightly regulated as they perform important biological functions in the cell. 
Sphingoid bases (Sa and So) are important in the regulation of cellular growth, 
differentiation, transformation, morphology, apoptosis and endothelial cell permeability 
while ceramide plays a role in cellular senescence, apoptosis and differentiation. The 
phosphorylated metabolite of sphingosine (sphingosine-1-phosphate) has proliferative and 
anti-apoptotic properties (Soriano et al., 2005, Riley et al., 2001).  Sphingolipids also form 
part of the localised regions called membrane micro-domains (lipid rafts). These lipid rafts 
affect various cellular functions such as calcium homeostasis, endocytosis, and protein 
sorting and signalling. Of major importance is the presence of these lipid rafts in the folate 
transporter which has been implicated in development of NTDs (Rao and Acharya, 
2008).There are currently more than 300 types of sphingolipids with sphingosine being the 
most commonly found in the backbone of mammalian sphingolipids (Menaldino et al., 2003).  
 
2.3.7 Sphinganine to sphingosine ratio as a useful biomarker for FB1 exposure 
The associated increase in sphinganine and sometimes sphingosine has led to the 
recommendation for use of Sa/So ratio as an indicator of fumonisin exposure (van der 
Westhuizen et al., 1999, Loiseau et al., 2007, Kim et al., 2001). Various studies have been 
conducted on animal, in vitro and human samples in order to demonstrate the importance of 
Sa/So ratio in FB1 exposure (Kim et al., 2001, van der Westhuizen et al., 1999, Wang et al., 
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1999, Loiseau et al., 2007).  Human plasma and urine from three rural African areas 
(Transkei, KZN & Bomet) were analysed for the concentrations of Sa and So. Although there 
was no statistical difference between the ratios in the three groups, plasma and urine samples 
from Transkei had the highest ratio compared to both KZN and Bomet (van der Westhuizen 
et al., 1999). Wang et al. showed a dose-dependent increase in urinary Sa and So in rats and 
this was also evident in porcine epithelium (Wang et al., 1999, Loiseau et al., 2007). Loiseau 
et al. found that FB1 affected sphingolipid metabolism in the porcine epithelium in a dose- 
and time-dependent manner (Loiseau et al., 2007). A concentration of 100M FB1 elicited a 
significant increase in sphinganine levels after day 2 of treatment whereas the low 
concentration (20M) took longer (6 days) to show a similar effect. The increase in 
sphingosine was however only observed after four days of treatment at both concentrations 
(20M and 100M) (Loiseau et al., 2007).Sphingoid bases are known inducers of cell death 
and this is highly dependent on their intracellular concentrations. 
 
2.4 Cell death 
Two morphologically distinct forms of cell death have been described, programmed cell 
death (apoptosis) and necrosis (Kerr et al., 1972). Necrosis is defined as accidental death; it is 
a pathological process which occurs when cells are exposed to a serious physical or chemical 
insult. Apoptosis is defined as programmed cell death and is responsible for cellular 
homeostasis during development, normal tissue turnover, and atrophy induced by endocrine 
and other stimuli, negative selection in the immune system and a substantial proportion of T-
cell killing. Morphological features for necrosis include loss of membrane integrity which 
begins with swelling of the cell and mitochondria, disintegration of other organelles and 
finally cell lysis. Biochemical features of necrosis include loss of regulation of ion 
homeostasis, random digestion of DNA and post-lytic DNA fragmentation. It is also 
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important to note that necrosis affects groups of cells, is not energy requiring, is evoked by 
non-physiological disturbance such as complement attack, lytic viruses etc. and also results in 
significant inflammatory response.  The features that characterise apoptosis are membrane 
blebbing and aggregation of chromatin at the nuclear membrane. It begins with cytoplasmic 
shrinkage (decrease in cell volume) and nuclear condensation and ends with formation of 
apoptotic bodies (Graf et al., 2007, Elmore, 2007). In contrast to necrosis, apoptosis affects 
individual cells, is induced by physiological stimuli and the apoptotic cell is phagocytosed by 
adjacent cells and macrophages. Thus the inflammatory response is evaded. In some diseases 
or injury states the two modes of cell death may co-exist and dependent on various factors the 
cells may die via necrosis or apoptosis. In the presence of high ATP, the cell undergoes 
apoptosis while reduced ATP levels result in necrotic death. Poly (ADP ribose) polymerase 




Apoptosis is an energy requiring process involving activation of proteins and enzymes. It is 
associated with pre-lytic DNA fragmentation, release of cytochrome C from mitochondria, 
activation of a caspase cascade and translocation of phosphatidylserine from the cytoplasmic 
to the extracellular side of the membrane (Krammer et al., 2007, Fadok and Henson, 2003). 
Several stimuli are known to trigger apoptosis, such as death receptors (TNF- and Fas 
Ligand), growth factor insufficiencies, toxins, oxidative stress and calcium influx through the 
plasma membrane. Apoptosis occurs via two mechanisms, the extrinsic (death receptor) 
pathway and the intrinsic (mitochondrial) pathway (Figure 2.5). Both these pathways result in 
activation of a caspase cascade which eventually leads to cell death. The intrinsic pathway is 
mediated by mitochondrial membrane permeabilisation and the release of cytochrome C 
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(mitochondria)and calcium (endoplasmic reticulum (ER)). The extrinsic (death-receptor) 
pathway (TNF and Fas) is dependent on ligand (Fas L) binding to the death receptor (Fas/ CD 
95)with resultant recruitment of the receptor-associated death domain resulting in formation 
of a signal complex which activates procaspase 8 and its downstream caspases. The CD95 
(APO-1 or Fas) receptor ligand system is important in homeostasis of the peripheral 
lymphoid compartment and cytotoxic T-lymphocyte-mediated target cell killing (Rahman et 
al., 2009, Neale and Mor, 2005).  
 
Caspases are cysteinyl-aspartate specific proteinases which cleave the protein targets at the 
aspartate region. They are synthesised as inactive zymogens with an N-terminal prodomain 
followed by a 20kDa and 10kDa subunit. Cleavage of the prodomain at specific aspartate 
residues leads to the activation of caspases. Thus far 12 different members of caspases in 
mammalian cells have been identified.  The caspases have been divided into three subgroups 
depending on their prodomain structure and substrate specificity. They are further 
differentiated according to their role in induction or execution of apoptosis as either initiator 
and/or execution caspases respectively. Initiator caspases (8, 9&10) possess a caspase 
recruitment domain (CARD) or death effector domain (DED). Activation of these caspases is 
responsible for the cleavage of cytoskeletal proteins such as actin, vimentin and fodrin which 
result in the characteristic blebbing of cell membranes. The characteristic “flip” of 
phophatidylserine from the inner to the outer leaflet of the membrane is also thought to be 
due to the action of activated initiator caspases which directly or indirectly cleave 
translocases/flippases. During these early stages of apoptosis, the process is still thought to be 
reversible and is important in signalling for cell-cell recognition and induction of the 




Activation of executioner/effector caspase (3, 6 &7) is the beginning of the irreversible 
component of the apoptotic process. These executioner caspases cleave a broad range of 
proteins which are critical for cellular survival such as nuclear envelope proteins (lamins A, 
B and C), proteins involved in DNA maintenance and repair (PARP), enzymes involved in 
the relaxation of the DNA-helix and separation of chromosomes during mitosis and 
intermediate filament proteins. Furthermore, executioner caspases also activate DNA 
fragmentation factor and other endonucleases which result in DNA fragmentation. Poly-
(ADP-ribose) polymerase catalyses the ADP-ribosylation of nuclear proteins at spontaneous 
DNA strand breaks sites using NAD as a substrate. This facilitates the repair of damaged 
DNA. It also plays a role in cell death by depleting the cell of NAD and ATP. In addition, 




-dependent endonucleases which cleave DNA during apoptosis. 
Thus, as a consequence of caspase cleavage, there is reduced DNA repair and increased 
chromosome damage. Lamins are important in maintaining the structural stability of the 
nucleus and are found on the inner surface of the nuclear membrane. Their cleavage leads to 
nuclear collapse and fragmentation. The main caspase responsible for the cleavage of lamins 





Figure 2.5: The figure depicts the two apoptotic pathways. The extrinsic pathway 
incorporates activation of death receptors and caspase 8 and the intrinsic (mitochondrial) 
pathway results in apoptosome formation and caspase 9 activation. Both pathways result in 
activation of initiator caspases specific for the pathway but converge at the level of activation 
of effector caspases that signify the beginning of the end (Rahman et al., 2009). 
 
2.5 The role of apoptosis in trophoblast development 
As in any tissue development, apoptosis plays a major role in placental development. It is 
important in the control of trophoblast turnover as well as maintaining a balance between 
proliferating and differentiating cells. Apoptotic events within the placenta begin with 
apoptosis in the cytotrophoblasts linked to syncytial fusion, the release of syncytial knots then 
makes up the final (execution) stages of apoptosis in the syncytiotrophoblasts. In order to 
ensure continuous replenishment of the syncytiotrophoblast layer, the apoptotic cascade is 
limited to a subset of cells which express transcription factors that inhibit proliferation and 
promote syncytial fusion while others are allowed to proliferate (Huppertz et al., 2006, 
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Kadyrov et al., 2006). Caspase 8 activity is evident in cytotrophoblast destined for syncytial 
fusion and hence apoptosis while the effector caspases are found in inactive forms in this 
layer.  The presence of anti-apoptotic proteins within the syncytiotrophoblasts ensures that 
the cells do not progress immediately into the final stages of apoptosis, i.e. formation of 
syncytial knots. The apoptotic activity of both cytotrophoblasts and syncytiotrophoblast is 
controlled at the mitochondrial level by inhibitors of apoptosis such as Bcl-2 family. The 
fused syncytial layer contains a mixture of newly-fused cytotrophoblast and old 
syncytiotrophoblast nuclei. The shape of newly fused nuclei is large, ovoid and rich in 
euchromatin while the pre-apoptotic ones are smaller and denser. The activity of execution 
caspases increases in the syncytial cells (nuclei) destined for syncytial knot formation.  
 
The apoptotic cascade in the extravillous cytotrophoblasts is poorly understood due to the 
inaccessibility of relevant tissue and cell types and as a result only end-stages of apoptosis 
have been documented. The Fas (CD95) and Fas ligand are present on the extravillous 
cytotrophoblasts. Similar to the differentiation of syncytiotrophoblasts, the extravillous 
trophoblasts also express different apoptotic markers at different stages. At the beginning of 
the invasive pathway they are resistant to apoptosis but later in the pathway the execution 
phases of apoptosis are activated. A study was done to evaluate the distribution of the 
different apoptotic markers within the placental tissue. The inactive form of caspase 8 
(initiator caspase) was restricted to the apical part of the cytoplasm in the syncytiotrophoblast 
and only weaker staining within the villous cytotrophoblasts. Activated caspase 3 is 
distributed evenly in the cytoplasm of syncytiotrophoblasts (Mancini et al., 1998, Huppertz et 
al., 1999, Huppertz et al., 2006, Heazell et al., 2008, Huppertz and Kingdom, 2004). Villous 
trophoblast apoptosis is high in pregnancies complicated by preeclampsia and intrauterine 
growth restriction. The exaggerated shedding syncytium in these pregnancies may therefore 
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result in cells undergoing a necrotic form of cell death where the whole process of apoptosis 
has not been completed, a term called aponecrosis (Huppertz and Kingdom, 2004).   
 
Apoptosis of invasive cytotrophoblasts from preeclamptic placentas is reportedly higher than 
in normotensive placentas (DiFederico et al., 1999, Genbacev et al., 1999, Kadyrov et al., 
2006, Huppertz et al., 2005). This indicates the role this process may play in the defective 
invasion (Allaire et al., 2000, Huppertz et al., 2006, Zhou et al., 1997). The Fas/FasL system 
is important in the immune protection of the developing foetus and hence is an integral part 
of the placental apoptotic machinery. Alterations in the Fas-FasL system in pregnancies 
complicated by preeclampsia have also been reported indicating the possible involvement of 
the Fas system in placental apoptosis (Neale et al., 2003, Neale and Mor, 2005). The FasL 
was localised on the villous cytotrophoblasts mainly in the first trimester while the receptor 
was localised to the microvillous surface of the syncytiotrophoblasts (Huppertz et al.,1998, 
Levy and Nelson, 2000, Neale et al., 2003).    
 
2.6 Fumonisin B1 and apoptosis 
Fumonisin B1 is known to induce apoptosis through various mechanisms. The disruption of 
sphingolipid biosynthesis is one of these mechanisms where the accumulation of sphingoid 
bases causes apoptosis. Fumonisin B1 is also known to induce apoptosis through the death 
receptor pathway by stimulating production of TNF- (He et al., 2001, Seefelder et al., 
2003a).                          
 
In the presence of FB1 there was increased expression of TNF- along with increased 
apoptosis in the liver and kidney of mice treated with FB1 while macrophages derived from 
animals treated with FB1also produced higher amounts of TNF- (Voss et al., 2002, Dugyala 
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et al., 1998, Ciacci-Zanella and Jones, 1999). A rabbit kidney cell (RK13) treated with a 
range of FB1 concentrations at varying duration showed no DNA fragmentation at all the time 
intervals studied but induced a significant concentration-dependent increase in micronucleus 
frequency (Rumora et al., 2002). Fumonisin B1 has also been shown to increase the activity 
of caspase 3 and also induce DNA damage in human fibroblasts (Galvano et al., 2002, 
Seefelder et al., 2003a). 
 
2.7 Rationale for the study  
The aetiology of preeclampsia remains elusive while the incidence and mortality is on the 
increase especially in developing countries. The populations in developing countries are 
dependent on a diet constituted by dietary staples such as maize and maize-based products. It 
is unfortunate that these staples are frequently contaminated by moulds. The toxic 
metabolites produced by these moulds have been implicated in various human and animal 
diseases. In this context, the role of the diet in preeclampsia has not been fully investigated. 
















3.1 Collection of samples 
 
Ethical approval was obtained from the Nelson R. Mandela School of Medicine (Ref. no. 
H025/05) and informed consent to draw blood and placental tissue was obtained from all the 
patients participating in this study after a full explanation of the study (Appendix A1). All the 
samples were collected from the King Edward VIII Hospital Labour ward, Durban, South 
Africa.  
 
A total of 40 black African patients were recruited in this study, 20 were preeclamptic (table 
3.2) and 20 were normotensive (table 3.1) pregnant women as controls. Venous blood 
samples (5ml) were collected into a lithium heparin tube (5ml) and ethylene diamine tetra 
acetic acid (EDTA) tube (5ml). Placenta was collected immediately following delivery and 
blocks of tissue were cut. Both sections were washed in physiological saline (0.9%) and 





Fixed placental tissue samples from both groups were processed for immunohistochemical 
analysis, routine haematoxylin and eosin staining and Hoechst. Serum samples were also 
analysed for the presence of fumonisin B1 (western blotting and high performance liquid 
chromatography (HPLC)) and sphingolipids (HPLC). Lipid peroxidation was determined in 




The mean age of the normotensive participants(Table 3.1) was 297.8 (range: 19-40 years) 
whilst the mean gestational age was 37 4.9 (range: 24-42 weeks). The mean systolic blood 
pressure was 11914.3 (range: 95-148mmHg) and diastolic blood pressure was 729.3 
(range: 50-90mmHg). 
 




  Age (years) 
Gest Age 
(/40 Weeks) SBP DBP 
1 30 38 148 80 
2 31 38 130 84 
3 37 38 130 90 
4 40 38 100 85 
5 26 39 110 70 
6 30 36 127 70 
7 39 40 117 77 
8 27 38 105 74 
9 24 40 115 69 
10 24 42 138 71 
11 36 40 95 70 
12 35 41 100 71 
13 22 28 104 50 
14 20 30 110 72 
15 37 37 131 60 
16 18 39 127 80 
17 18 24 130 74 
18 19 30 116 65 
19 40 39 114 66 
20 22 41 130 62 
Mean  29 37 119 72 




The mean age of preeclamptic patients (table 3.2)was 265.9 (range: 19-40) while the mean 
gestational age was 345.1 (range: 24-40). The mean systolic blood pressure was 1569.1 
(range: 145-174) and diastolic blood pressure was 959.3 (range: 78-110). Proteinuria was a 
defining characteristic in these patients and ranged from 0.3g/l to 3.0g/l via dipstick test.  
 
Table 3.2:  Demographics of hypertensive patients 










1 27 35 155 100  ++ PE 
2 26 27 151 93  ++ PE 
3 22 28 170 100  ++ IE 
4 32 34 163 101  + IE 
5 40 27 150 90  ++ PE 
6 32 37 152 103  +++ PE 
7 31 37 162 104  + PE 
8 27 36 162 80  + PE 
9 22 36 162 86  ++ PE 
10 34 38 145 83  + PE 
11 23 40 152 102  ++ PE 
12 21 39 168 110  +++ PE 
13 31 28 160 101  +++ PE 
14 20 39 150 110  + PE 
15 19 34 164 87  ++ PE 
16 21 40 151 95  +++ PE 
17 22 24 148 90  + PE 
18 19 39 148 78  + PE 
19 30 29 174 99  ++ PE 
20 20 31 159 95  ++ PE 
mean 26 34 157 95   
SD 6.0 5.1 8.2 9.3   
 
Key to the tables: 
SBP: Systolic blood pressure 
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DBP: Diastolic blood pressure 
PE: preeclampsia 
IE: Imminent eclampsia 
SD: Standard deviation 
Trace amounts of protein in the urine = 0.1g/l 
+ = 0.3g/l 
++ = 1.0g/l 
+++ =  3.0g/l 





















Qualitative and quantitative analysis of fumonisin B1, sphingolipids and lipid peroxides in 
the serum of preeclamptic and normotensive pregnant women. 
 
4.1     INTRODUCTION 
Serum represents an important route by which xenobiotics/digested foods are transported 
from their site of absorption to their target sites. For hydrophobic molecules, proteins present 
in the serum are responsible for performing this function. The most important serum protein 
involved in the transport of xenobiotics is albumin. Albumin is rich in lysine residues, which 
allows xenobiotics to bind to the positively charged side chain (Kawakami et al., 2006). The 
carcinogenic mycotoxin, aflatoxin B1, forms adducts with lysine residues in albumin 
(Sabbioni et al., 1987). Fumonisin B1is a polar mycotoxin that utilises the gastrointestinal 
tract as a route of exposure. Serum therefore represents an important mechanism for 
FB1delivery to target sites in the body. 
 
The hydrophilicity of FB1 means that it does not require a transport protein to reach its target 
sites. However, the structure of FB1 would also facilitate binding of FB1 to serum proteins 
through interactions with its carboxyl and amino groups. The carboxyl groups have been 
shown to interact with the positively charged groups on the protein whilst the terminal amino 
group interacts with negatively charged amino acids on the protein. Thus proteins rich in 
positively charged amino acids such as lysine would interact with FB1 through the epsilon 
amino group found on the lysine residue. 
 
The question therefore is „Does FB1 bind to serum proteins?‟  This question has been 
partially addressed in previous studies which looked at interaction of FB1 with various 
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proteins from biological and non-biological samples. Seefelder et al. showed that FB1 does 
interact with proteins and carbohydrates from food samples, whilst other studies showed the 
interaction in oesophageal and liver tissue samples (Seefelder et al., 2003b, Myburg et al., 
2009, Cawood et al., 1994).  
 
It may now be considered an established fact that the mechanism of FB1 toxicity is due to 
disruption of sphingolipid metabolism at the level of ceramide synthase. The inhibition of 
ceramide synthase results in an accumulation of sphinganine (Sa) and sphingosine (So). It is 
the alteration in the ratio of these key molecules in serum and also urine that is now 
considered a biomarker for FB1 exposure.  
 
Proteomics is an invaluable technique in environmental and occupational health studies. The 
environment plays a major role in many human processes and thus by using this method 
valuable information at the cellular and molecular levels can be obtained. Therefore this 
study qualitatively (western blotting) and quantitatively (high performance liquid 
chromatography (HPLC)) determined whetherFB1 and intermediates of the sphingolipid 
pathway, sphinganine and sphingosine, are present in serum samples of normotensive and 
preeclamptic pregnant women.  
 
Fumonisin B1 toxicity is often associated with increased oxidative stress through various 
mechanisms. Reactive oxygen species such as superoxide interact with polyunsaturated fatty 
acids to form lipid hydroperoxides. One of the by-products of this peroxidative process is 
malondialdehyde (MDA).Thus; the presence of lipid peroxides in the form of MDA in the 




4.2    MATERIALS AND METHODS 
 
4.2.1  Materials  
Bovine serum albumin (BSA) was purchased from Roche Diagnostics and diaminobenzidine 
(DAB) chromogen tablets were purchased from DAKO Corporation, Southern Cross 
Biotechnology. Monoclonal primary antibody (mouse anti-FB1) was purchased from Neogen 
(USA) and secondary antibody (rabbit anti-mouse IgG) was purchased from Capital Labs. All 
the sodium dodecyl sulphate- polyacrylamide gel electrophoresis (SDS-PAGE) chemicals 
and reagents employed in the making of buffers were purchased from BioRad, South Africa. 
Thiobarbituric acid (TBA) and butylatedhydroxytoluene (BHT) were purchased from Capital 
laboratories (South Africa).High performance liquid chromatography (HPLC) grade 
consumables (methanol, acetonitrile, 2-mercaptoethanol, sodium dihydrogen phosphate, 
ammonium hydroxide, chloroform, silica, anhydrous sodium sulphate and potassium 
hydroxide) were also purchased from Merck Chemicals, South Africa whilst O-
pthaldialdehyde and strong anion exchange cartridges were purchased from Capital Labs, 
South Africa. All other chemicals employed in the making of buffers and solvents were 




4.2.2.1 Sample preparation 
Venous blood, collected in vacutainers (clot activator) prior to delivery, and serum was 
obtained by centrifugation at 1 491rpm for 30 minutes (Eppendorff 5408R centrifuge, 
Hamberg, Germany). The serum was aliquoted and then stored at -20
0




4.2.2.2 The Bicinchoninic Acid (BCA) Assay 
The BCA assay was used to determine crude protein concentrations for subsequent 
standardisation. A bovine serum albumin standard (1mg/ml) was prepared and serial dilutions 
(Appendix B1) were prepared with storage buffer, pH 7.5 (Appendix B2). Serum protein 
samples (25l) from normotensive and preeclamptic patients were diluted (1:100) with 
storage buffer and then loaded into a 96-well plate along with the serial dilutions (25l) in 
duplicate. A BCA working solution (200l, Appendix B1.1) was then added into each well 
and incubated for 30minutes at 37
0
C. The plate was then spectrophotometrically read on a 
Biotek µQuant microplate reader at 562nm. A standard curve was then prepared using the 
averaged absorbance values obtained from the BSA standards and protein concentrations 
were extrapolated from the standard curve (Appendix B1.2). These protein concentrations 
were then standardised to 200g/ml with storage buffer.    
 
An aliquot of standardised sample (100µl) was mixed with 1xSDS reducing (sample) 
buffer(100µl) (Appendix B3.3). The protein samples were then heated to 100
o
C for 5 minutes 
to denature them.  
 
4.2.2.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
The 10% resolving gel was prepared (Appendix B3.1) and poured into the assembled glass 
plates (enough to leave space for the stacking gel). Water was poured over the separating gel 
in order to prevent oxygen from diffusing into the gel and preventing polymerisation. The gel 
was left to polymerise for approximately an hour. The water was then poured off and dried 
with fibre-free filter paper. Stacking gel (4%) (AppendixB3.2) was then overlaid on top of the 
resolving gel, the combs were inserted and the gel left to polymerise as before. The combs 
were then removed and gels were loaded on electrophoresis apparatus. Samples (30l) and 
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5l of molecular weight marker were then loaded into their respective wells and allowed to 
electrophorese at 150V for 1 hour in electrode (running) buffer, pH 8.3 (Appendix B5). The 
gels were then stained with a Coomasie blue stain (Appendix B4.1.1) for 30 minutes, 
destained with destaining solution 1 (Appendix 4.2) for 1 hour and finally left in destaining 
solution 2 (Appendix 4.3) overnight. The gels were analysed using a ChemiDoc XRS gel 
documentation system (BioRad, South Africa). 
 
4.2.2.4 Western blot analysis of serum for FB1 
Following electrophoresis, the separated proteins were electro-transferred to an equilibrated 
polyvinylidenedifluoride (PVDF) membrane for one hour in transfer buffer (Appendix B6). 
After transfer the membrane was blocked with 5% non-fat dry milk in Tris-buffered saline 
with 0.1% Tween 20 (TTBS) (Appendix B7), the membrane was immuno-probed with 
monoclonal anti-FB1(1:1000 in 1% BSA, Neogen, USA) for 1 hour at room temperature 
(RT). The PVDF membrane was then subjected to 5 washes (10 minutes each with gentle 
agitation) with TTBS.  The membrane was then incubated in horse radish peroxidase (HRP)-
conjugated secondary antibody (rabbit anti-mouse 1:10000; Bio-Rad) for 1 hour at RT. After 
further washing, antigen-antibody complexes were detected by chemiluminescence using the 
Immune-star HRP substrate kit (Bio-Rad).  Chemiluminescent signals were detected with 
the Chemi-doc XRS gel documentation system and analysed using the quantity one software 
(Biorad, South Africa). Band intensity analysis was conducted on the resultant bands. 
 
4.2.2.5 High performance liquid chromatography -Quantitation of serum FB1 
The FB1 in serum samples was extracted and purified using the method described by van der 
Westhuizen et al. (2001). Pre-conditioning of strong anion exchange (SAX) cartridges was 
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achieved by application of 5ml of methanol-water (3:1 v/v) to the column. The sorbent was 
successively washed with 5ml of methanol-water (3:1 v/v) and 5ml of methanol.  
 
An aliquot (500l) of serum was deproteinised by the addition of 2.5ml of methanol. The 
protein was precipitated by centrifugation at 5 000rpm for 10 minutes at RT (Eppendorff 
5804R). The supernatant was removed and applied to a pre-conditioned strong anion 
exchange (SAX) cartridge. Fumonisin B1 was then eluted from the sorbent with 10ml of 5% 
acetic acid in methanol using a Varian Vac Elute system (Capital laboratory supplies) at a 
flow rate of 1ml/min. The eluate was evaporated to dryness at 60
o
C and the residue was re-
dissolved in 100l of acetonitrile- water (1:1 v/v) and allowed to stand for 5 minutes prior to 
derivatisation. The FB1 was derivatised using O-pthaldialdehyde (OPA) derivative (Appendix 
C1) prior to analysis by reverse phase HPLC (RP-HPLC). Derivatised samples were prepared 
by mixing 40l of the extracted sample with 80l of the OPA reagent. RP-HPLC analysis of 
the serum samples was carried out under isocratic conditions (flow rate 1ml/min) using 
methanol-0.1M NaH2PO4 (29:71) buffer (pH3.3). Injection of 50l of derivatised sample was 
performed in duplicate in order to confirm reproducibility. The HPLC system employed 
consisted of a spectra physics P2000 binary pump, an autosampler and an FL2000 
fluorescence detector (excitation-335nm & emission 440nm ThermoSeparation production) 
with a Waters NovaPak C18 column ( Waters, Microsep, SA) and an HIRB-10C guard 
column (Hichrom Ltd, SMM Instruments) attached. The results were analysed using the 
Chromquest 4 software.  
 
4.2.2.6 Analysis of sphinganine and sphingosine from serum  
Serum (500l) was deproteinised in methanol (2ml), vortexed and centrifuged for 10 minutes 
at 5 000rpm (Eppendorff 5408R). The supernatant (2ml) was transferred into a clean 
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centrifuge tube and 1.9ml of water, 1.2ml of 0.35M NH4OH and 4ml chloroform (CHCL3) 
were added and then centrifuged for 10 minutes at 5 000rpm. After centrifugation, the top 
layer was aspirated and discarded.  A column was prepared by packing 0.5g of silica and 5g 
of anhydrous sodium sulphate (Na2SO4) and conditioned with CHCL3 (4ml).  The sample 
(3ml) was then loaded onto the column and washed with 1ml CHCL3, followed by elution 
with 10ml of CHCL3: CH3OH: NH4OH (20:20:0.8, v/v/v) and dried under a gentle stream of 
nitrogen at 38
0
C. The dried residue was re-dissolved in 1ml 0.125M potassium hydroxide 
(KOH)/ CH3OH: CHCL3 (4:1) and kept at 38
o
C.  After 1.5 hours the samples were cooled on 
ice and thereafter re-dissolved in 1ml of CHCL3 and 5ml alkaline NH4OH.  The mixture was 
centrifuged at 1200xg for 10 minutes. The top layer was discarded and bottom layer dried 




High performance liquid chromatography was performed on the OPA derivatised samples. 
The derivatised sample (50l) was injected into the HPLC system consisting of a spectra 
physics P2000 binary pump, an autosampler and an FL2000 fluorescence detector 
(excitation-335nm & emission 440nm;ThermoSeparation production) with a Waters NovaPak 
C18 column ( Waters, Microsep, SA) and an HIRB-10C guard column (Hichrom Ltd, SMM 
Instruments) attached. Samples were pumped in the isocratic mobile phase of 
methanol/0.05M potassium phosphate buffer (pH 7.4) (91:1) and the flow rate controlled at 
2ml/min. The results were then analysed using the Chromquest 4 software. 
 
4.2.2.7 Thiobarbituric acid reactive substances (TBARS) - analysis of lipid peroxidation 
in serum 
Equal amounts (500µl) of serum and 2% H3PO4 were added to a glass tube. The solution was 
then aliquoted into two glass tubes, one designated sample (400µl) and another, the 
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blank(400µl). To each tube, 7% H3PO4 (200µl) was added followed by addition of TBA/BHT 
(400µl) to the sample tube and 3mM HCl (400µl) to the blank tube. The pH of all samples 
was adjusted to pH 1.5 using 1M HCL and then heated to 100
0
C for 15 minutes. Following 
cooling to room temperature, butanol (1.5ml) was added to each tube and vortexed for 40-
60seconds.The butanol phase (top) was aliquoted into a centrifuge tube and centrifuged at 
13200rpm for approximately 6 minutes. The lipid peroxides were then measured 
spectrophotometrically at dual wavelength (532nm, 600nm) and the following equation was 
used to calculate the concentration of MDA in the samples: 
                            
     
 
 
4.2.2.8 Statistical analysis 
The results were analysed using the Graphpad Prism 5 software. A student‟s t-test was use for 
analysis. Data is presented as mean standard error of the mean (SEM). A p-value of 0.05 
was considered statistically significant. 
 
4.3      RESULTS  
 
Serum samples were both quantitatively and qualitatively analysed for the presence of FB1.  
Western blotting was used to determine the presence of FB1 in serum whilst HPLC was used 
to quantify the FB1 in serum. An albumin standard was used as a method control; one 
albumin fraction was spiked with FB1 whilst the other was unspiked and served as a negative 






Western blot analysis of serum 
Fumonisin B1 was found in both normotensive and preeclamptic serum samples (Figure 4.1). 
The albumin negative control showed the absence of FB1, whilst the positive had a visible 
band. 
 
Figure 4.1: A representation of western blot banding pattern for serum samples from 
normotensive patients (N1-N3) and preeclamptic patients (P1-P3). Pure albumin (A) and 
albumin spiked with FB1 (AF) served as negative and positive controls respectively.  
 
The densitometric analysis of the membrane (Figure 4.2) revealed significantly higher band 




































Figure 4.2: Band intensity analysis of sera from preeclamptic and normotensive women. * 






Quantitation of FB1 (HPLC) 
Serum samples were also analysed for the presence of FB1 and the levels of sphinganine and 
sphingosine using HPLC (Table 4.1).   
 
Table 4.1 Relevant patient demographics and FB1, sphinganine and sphingosine values 
(values presented as mean ± SEM) 
Variable  Normal (n=20) Preeclampsia (n=20) p-value 
Age 28.8±1.732 26 ±1.335  











Proteinuria trace 1.155±0.223  
Mean concentration of 
FB1 
16.59 ± 3.141 36.82 ± 9.007 
0.03 
Mean concentration of 
Sa 
0.034 ± 0.010 0.088 ± 0.021 
0.04 
Mean concentration of 
So 
0.017 ± 0.005 0.025± 0.006 
0.3 
 
The concentration of FB1 in serum was analysed using HPLC and the concentration was 
calculated using the Chromquest 4 software. A typical chromatogram of FB1 (Figure 4.3), 
demonstrating the retention time of FB1 and the results are presented in Table 4.1. Retention 















Figure 4.3: A representative HPLC chromatogram from patient‟s serum showing FB1 
retention time (5.843) and an estimated concentration of 0.679M. 
 
Preeclamptic sera had significantly higher (p = 0.03) concentrations of FB1 (36.82 ± 9.007; 0-
114ng/ml) compared to the normotensives (16.59 ± 3.141; 0-25ng/ml) (Table 4.1 & Figure 
4.4). Non-detectable levels of FB1 were observed in one preeclamptic sample and two 
normotensive samples. The highest concentration detected in preeclamptic samples was 










Figure 4.4: Graphical presentation of serum concentrations of FB1 from normotensive (n=20) 
and preeclamptic (n=20) women. FB1 was significantly higher in preeclamptics (p=0.03). 
Two-tailed 95% confidence interval* indicates the results were significantly different from 
controls (Mann Whitney test). 
 
Quantification of sphinganine and sphingosine (HPLC) 
Serum samples from both normotensive and preeclamptic women were analysed for the 
presence and concentration of sphinganine and sphingosine and a chromatograph was 
































Figure 4.5: A representative chromatograph of sphinganine (Sa)/sphingosine (So) analysis 
from serum of pregnant women showing the retention times and peaks for Sa and So. 
 
The mean concentration (0.088 ± 0.021; range 0-0.192M) of sphinganine was significantly 
higher (p=0.04) in preeclamptics compared to normotensives (0.034 ± 0.010; range 0-
0.086M) (Table 4.1 & Figure 4.6). There was no statistical difference in the sphingosine 
concentrations between the normotensives and preeclamptics (p=0.3) (Table 4.1 & Figure 
4.7). Preeclamptic samples (0.025± 0.006 range 0-0.003M) were slightly higher than that 
found in normotensive samples (0.017 ± 0.005; 0.002-0.028M). Two samples from each 
group had non-detectable levels of sphingosine whilst two samples in normotensives also had 









Figure 4.6: Sphinganine concentrations from normotensive and preeclamptic sera. 
Significantly high concentrations of sphinganine were observed in preeclamptics compared to 
the normotensives. * indicates statistically significant difference between the means (p=0.04) 











Figure 4.7: Graphical representations of sphingosine concentrations from normotensive and 
preeclamptic samples. There was no significant difference. T-test, Welch correction p>0.05, 
Two-tailed, 95% confidence interval 



























































The levels of lipid peroxidation in serum were measured using the TBARS assay. There was 
a slight but non-significant increase in lipid peroxides as indicated by MDA in preeclamptic 





































Figure 4.8:Malondialdehyde (MDA) concentrations in normotensive and preeclamptic sera. 
The MDA concentration was non-significantly higher in preeclamptic sera compared to the 
normotensives. p0.05, unpaired t-test with Welch‟s correction. 
 
4.4      DISCUSSION 
Although preeclampsia has been studied extensively, its aetiology still eludes researchers and 
thus it is imperative to investigate other possible aetiological agents. The diet of the African 
community is comprised primarily of maize and maize-based products and a study by 
Chelule et al. showed high levels of FB1 in rural maize samples compared to their urban 
counterparts (Chelule et al., 2001). This finding coupled with the fact that the Eastern 
coastline of South Africa has one of the highest incidence of preeclampsia in the country, 




To date, no study has shown the presence of FB1-protein conjugates in pregnant women. This 
current study demonstrated that FB1 forms conjugates with albumin, a serum protein rich in 
lysine residues (Figure 4.1). The tricarballylic acid (TCA) moieties in FB1 will allow strong 
binding to the ε-amino groups of the lysine residues. Albumin is the major serum protein in 
plasma and its important functions are to regulate colloid osmotic pressure and transport 
(Baynes and Dominiczak, 2009).  
 
This study showed that FB1 is present in the blood of normotensive and preeclamptic women. 
It is important to note that the FB1 detected using western blotting represents only 
bound/conjugated FB1, while HPLC quantifies both bound and free FB1. The levels of bound 
FB1 (FB1-serum conjugates) were higher in normotensive sera compared to preeclamptics 
(Figure 4.2).This is in stark contrast to the quantitative analysis (HPLC) which showed the 
opposite effect (Figure 4.4). Preeclampsia is a condition of pregnancy marked by proteinuria 
which results in a loss of serum proteins such as albumin (Thangaratinam et al., 2009). Thus, 
preeclamptics may be characterised as having reduced concentrations of albumin in their 
serum. Extensive loss of protein was observed in all hypertensive patients compared to 
normotensive women who have no (trace levels) protein loss (Table 4.1). Therefore due to 
proteinuria, very little albumin is available for binding to FB1 in preeclamptic sera and much 
of the FB1 remains free in the serum. In comparison, normal albumin levels prevail in 
normotensive sera leaving more available to bind FB1 and hence the high relative band 
intensity observed in this group. This provides a plausible explanation for the reduced FB1-
protein adducts observed in the preeclamptic sera.  
 
In addition, preeclamptic sera contained high levels of lipid peroxides compared to 
normotensive counterparts indicating increased production of reactive oxygen species (ROS) 
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that may interact with cellular macromolecules such as protein, lipids and DNA. In the 
current study it is reasonable to hypothesise that the reduction in albumin-FB1 adducts in 
preeclamptic sera may be due to the fact that in addition to the proteinuric loss, the available 
albumin is oxidised by ROS and is thus unavailable to bind to FB1. The levels of oxidised 
albumin have been measured in several diseases such as stroke, diabetes and renal failure as 
an indicator of oxidative stress. The use of MDA as an indicator of lipid peroxidation has 
come under scrutiny due to the non-specific interaction of TBA with other molecules such as 
sugars, urea, proteins and alkanals in addition to MDA. Therefore in addition to measuring 
MDA it is recommended that other products of lipid peroxidation be measured using highly 
specific methods such as HPLC and GC-MS. A measurement of oxidised albumin in the 
current study would have strengthened the arguments (Devasagayam et al., 2003, Moon et 
al., 2011). Another plausible explanation may be that the ROS interact with polyunsaturated 
fatty acids on the glomerular membrane, making it leaky and facilitating the loss of albumin 
via this route. 
 
As mentioned, qualitative analysis of FB1 by HPLC provides the total concentration of FB1 
present (bound and unbound). Thus, higher levels of FB1 are seen in preeclamptic women 
compared to their normotensive counterparts (Figure 4.4). These results concur with a 
previous study by Moodley et al. who first reported on the presence of FB1 in serum of black 
South African women from the same Hospital. Eclamptic and preeclamptic serum samples 
showed higher FB1 concentrations compared to their normotensive counterparts (Moodley et 
al., 2001). This is possible as the staple diet of all patients in the study is maize and as a result 
of this dietary pattern, the subjects would be chronically exposed to FB1. Fumonisin B1 is a 
polar molecule and is rapidly excreted; therefore the high levels observed in the preeclamptic 
women may indicate an increase in absorption, reduced excretion or accumulation. Due to the 
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chronic exposure through maize it is reasonable to postulate that FB1 would accumulate over 
time either through binding to serum or tissue proteins which would serve as reservoirs for 
the mycotoxin. This conjugation with proteins and reduced excretion may therefore prolong 
its toxic action(s) in these patients and possibly also in utero.  
 
Fumonisin B1 is known to interact with macromolecules through its TCA moieties and 
terminal amino group. The amino and thiol groups in proteins interact with the TCA and 
terminal amino group on the FB1 backbone respectively (Seefelder et al., 2003b).In addition, 
TCA moieties FB1 are able to conjugate to other macromolecules such as carbohydrates 
(Seefelder et al., 2003b, Hopmans et al., 1997). Hopmans et al. showed the excretion of FB1 
and its metabolites (FB1-fructose adduct, hydrolysed FB1) in rats and found that 50% of FB1 
was excreted un-metabolised while the FB1-fructose adduct was absorbed to a higher degree 
than the hydrolysed form (Hopmans et al., 1997). This therefore indicates the role that 
macromolecules play in prolonging the half-life of toxins. The binding of FB1 to proteins 
such as albumin may therefore serve as a mechanism to enhance its absorption, prolong its 
toxicity by extending its retention in the body. 
 
As a consequence of FB1 toxicity, sphinganine is elevated in most tissues and cells to a 
greater degree than sphingosine (Desai et al., 2002). The current study showed significantly 
higher levels of sphinganine and sphingosine in preeclamptic patients compared to their 
normotensive counterparts. This is not surprising considering the higher levels of FB1 
observed in these subjects would have a greater impact in inhibition of sphingolipid 
metabolism resulting in the observed increase in these sphingoid bases. These results concur 
with other human studies in that sphinganine concentrations were elevated in the presence of 
FB1 (van der Westhuizen et al., 1999, Castegnaro et al., 1998).Van Der Westhuizen et al. 
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were the first to show the increase in Sa and associated Sa/So ratio in blood and urine of rural 
Eastern Cape communities (van der Westhuizen et al., 1999). However, they concluded that 
the sphinganine/sphingosine ratio may not be sensitive enough to act as a biomarker for FB1 
exposure in humans. Various animals were also studied to demonstrate the importance of the 
sphinganine/sphingosine ratio as a biomarker for FB1 exposure. Following a single gavage 
dose of FB1, the serum of vervet monkeys showed an elevation in the ratio compared to 
controls (van der Westhuizen et al., 2001a). Low concentrations of FB1 were shown to be 
effective in elevating the sphinganine/sphingosine ratio following repeated dosing (van der 
Westhuizen et al., 2001b). Fumonisin B1 was also shown to increase the ratio in male Wistar 
rats (Domijan et al., 2007).  
 
This is the first preliminary report on the sphingolipid concentrations in pregnant women and 
in agreement with van der Westhuizen et al. A comprehensive study of the 
sphinganine/sphingosine ratio in pregnant women will have to be conducted to support its use 
as a biomarker of FB1 exposure. A recent report has provided evidence for the use of urinary 
FB1 concentrations as a biomarker of exposure and therefore future studies in pregnant 
women should also look into using this method for biomarker purposes (van der Westhuizen 
et al., 2001a, van der Westhuizen et al., 2011). Elevated sphinganine has been associated 
with decreased cell viability, DNA fragmentation, loss of regulation of differentiation and 
apoptotic morphology. Thus the high levels of sphinganine observed in preeclamptic samples 





4.5     CONCLUSION 
The presence of FB1 in sera of pregnant women indicates the chronic exposure of pregnant 
women to mycotoxins. The serum concentrations of FB1 were higher in preeclamptic 
compared to normotensive patients. This study shows that FB1 conjugates with albumin, 
thereby interfering with its normal physiological functions.  It is tempting to say that due to 
the findings in the study FB1 may be an aetiological agent in the development of 
preeclampsia. However it must be noted maize is not only contaminated by Fusaria spp. 
moulds but other species of moulds may co-occur and as a result affect the toxicity of FB1. 
Therefore a mycotoxin survey of the blood of rural communities which are heavily reliant on 
maize may demonstrate this possible interaction.  Further studies also need to be conducted 






















Analysis of placental samples for the presence of fumonisin B1, apoptotic markers and 
lipid peroxides 
 
5.1      INTRODUCTION 
Since its discovery, microscopy has become an indispensable tool in the study of cellular 
structure and function. The use of the different types of microscopes like electron and light 
microscopy has provided the possibility of studying the ultra-structure of different organs and 
tissues and hence provide important information about their fine structure (Javois, 1999).  
 
Light microscopy allows visualisation of tissue or cellular architecture using various dyes. 
Cell staining is a powerful method to demonstrate both the presence and subcellular location 
of a particular molecule of interest. Dyes are aromatic benzene ring compounds or derivatives 
that possess colour and the ability to bind to tissues. Chromophores confer colour to the dye 
and alter the light resonance properties of the compound resulting in unequal absorption 
when white light is passed through. The colour emitted by a specific object is dependent on 
the colour spectrum when white light falls on it. Primary stains highlight the element to be 
studied while secondary stains have a high affinity for background materials and are usually 
of the contrasting colour (Javois, 1999). 
 
Although fixation is an integral part of tissue preservation, it also affects the interaction of 
tissues with various stains. Certain fixatives may either enhance or inhibit dye uptake through 
modifications of tissue proteins. Formalin for instance, forms crosslinks with proteins and 
masks cationic binding sites for anionic dyes suppressing acidic dye (eosin) uptake, while 
anionic binding sites are exposed enhancing the basophilic (haematoxylin) nature of nuclei. 
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Immunohistochemistry (IHC) is defined as the identification of a tissue constituent in situ by 
means of a specific antigen-antibody reaction where the antibody has been tagged with a 
visible label (Javois, 1999). It was used in this study to facilitate the detection of antigens at 
the light microscopy level. The peroxidase anti-peroxidase (PAP) method (Figure 5.1) was 
applied to immunolocalise FB1 within placental tissues. This method, pioneered by 
Sternberger in 1979 involves the use of immunological sandwich amplification and the horse 
radish peroxidase enzyme (HRP) to evoke a signal that is rendered visible using 3, 3-
diaminobenzidine tetrahydrochloride (DAB). The distinguishing feature of the procedure is 
the PAP immune complex.  The anti-peroxidase antibodies are from the same animal species 
that produced the primary antibody. The secondary linking antibody is raised in a different 
animal species from the primary antibody. The HRP produced from the horse radish plant is a 
40kDa protein with immunogenic capabilities. 
 
 
Figure 5.1: Illustration of molecular interactions of the PAP technique depicting the various 
levels that facilitate amplification of the signal, adapted from (Javois, 1999).  
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The advantage of this procedure is that the PAP complex remains soluble and the enzymatic 
activity of the peroxidase is not affected by the attached antibodies. The background 
problems encountered with this method may be alleviated by the use of detergents and 
extensive washing steps.  
 
Formalin fixation and embedding in paraffin wax are important in the preservation of tissue 
morphology. However, they have the potential to damage, destroy or mask antigenic sites and 
thus reduce the reactivity of antigens with antibodies during immunohistological 
preparations. Even though snap frozen tissue may be used as an alternative to paraffin 
embedded tissue, the former method still offers well-preserved tissue architecture and cellular 
morphology superior to frozen tissue (Javois, 1999, Shi et al., 1991).  Treatment of proteins 
or peptides with formaldehyde resulted in four major modifications including, formation of 
hydroxymethyl adducts, Schiff base adducts, 4-imidazolinone adducts and methylene bridges. 
In order to overcome these challenges, antigen retrieval techniques have been developed to 
unmask the epitopes. The earliest discovery was the use of protease digestion which was not 
effective in unmasking most epitopes and led to the discovery of heat induced epitope 
retrieval (HIER) by employing heating techniques such as microwave, pressure cooker and 
autoclave heating in various solutions (Shi et al., 2001b, Shi et al., 2001a, Fowler et al., 
2011, Pileri et al., 1997). Due to its proven efficacy and affordability, the microwave oven 








5.2      MATERIALS AND METHODS 
 
5.2.1 Materials 
All routine microscopy reagents were purchased from Merck chemicals (South Africa). The 
antibodies for Fumonisin B1, caspase 3 and Fas and secondary antibodies were purchased 
from Capital laboratories (South Africa).Bovine serum albumin (BSA) was purchased from 
Roche Diagnostics and diaminobenzidine (DAB) chromogen tablets were purchased from 
DAKO Corporation, Southern Cross Biotechnology. Mayer‟s haematoxylin and eosin stains 
were purchased from Merck Chemicals (South Africa). Hoechst 33258 stain was purchased 
from Capital Laboratories (South Africa). Thiobarbituric acid and butylated hydroxytoluene 
were purchased from Capital Laboratories (South Africa).All general laboratory consumables 
were purchased from Merck Chemicals (South Africa).  
 
5.2.2 Methods 
5.2.2.1 Morphological analysis of placental samples: Tissue processing 
Placental tissues were fixed in formal saline as described in chapter 3. An adapted version of 
the automated tissue processor was used to manually process the tissue. Briefly, placental 
tissue samples were fixed in 10% formal saline for 12-24 hours at 24
o
C and then dehydrated 
through increasing changes of ethanol (10%-100%). The tissues were then cleared in 2 
changes of xylene (1hr each) and transferred to melted paraffin wax for one hour and left in 
fresh wax overnight (60
o
C). The sections were embedded in fresh paraffin wax for 20 
minutes (20
o
C) and allowed to solidify. 
 
Prior to sectioning the tissue blocks, glass slides were coated with poly-L-lysine (Sigma). It is 
an adhesive subbing solution for immunohistochemistry and routine histological staining 
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preparations. The polycationic nature of poly-L-lysine allows interaction with anionic sites of 
tissue sections resulting in strong adhesive properties. Wax embedded tissue blocks were 
sectioned using a Leica RM 2025 microtome and mounted on poly-L-lysine coated slides. 
The sections were heat fixed (60
o
C) onto slides and stored at room temperature for further 
analysis. 
 
Haematoxylin and Eosin (H & E) staining 
Heat fixed placental sections were deparaffinised in 2 changes of xylene (100%) (10 minutes 
each) followed by rehydration in decreasing grades of ethanol, absolute (2 changes, 5 minutes 
each); 95% and 70% ethanol (2 minutes each). The sections were then briefly washed in 
deionised water and stained with Mayer‟s haematoxylin (Appendix D1.1) for 5 minutes at 
room temperature. Thereafter, the sections were allowed to stand under a gentle stream of tap 
water for 10 minutes and rinsed in distilled water. The sections were then rinsed in 95% 
ethanol (10 dips) and counterstained with eosin-phloxine B solution (Appendix D1.2) for 
30seconds to 1 minute. The sections were then dehydrated through increasing grades of 
ethanol and cleared in 2 changes of xylene (5 minutes each) and mounted with DPX. These 
sections were then viewed using a light microscope (Olympus IX51), images were captured 
using analysis LS software. 
 
5.2.2.2 Immunohistochemical analysis of placental tissue for fumonisin B1 
Tissue sections picked up on poly-L-lysine coated slides were analysed for the presence of 
FB1 using IHC. All antibodies were diluted to a pre-determined appropriate dilution factor 
using 1% (w/v) BSA in Tris-buffered Saline (TBS) (0.05M, pH 7.2) solution as the diluent. 
The use of method controls involved omission of the primary antibody and its replacement 
with TBS on the tissue specimen.  Antigen retrieval was conducted to unmask antigenic 
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determinants that would have been affected by fixation and subsequent processing (Javois, 
1999). 
 
5.2.2.3 Antigen retrieval 
Tissues sections were dewaxed and dehydrated as mentioned in 5.2.2.1 above. The slides 
were transferred to plastic Coplin jars filled with HIER buffer(10mM sodium citrate buffer, 
pH 6, Appendix D3) and placed in the microwave (with loose-fitting caps) and heated at 
maximum power (700-1000W). The solution was allowed to boil for 3-5 minutes while 
constantly replenishing evaporated solution. The cycle was repeated 2-3 times and then 
allowed to cool to room temperature (approximately 20 minutes). Immunohistochemistry was 
performed immediately following this procedure. 
 
5.2.2.4 Immunohistochemistry 
A Pap pen was used to create reagent wells immediately following antigen retrieval. 
Endogenous peroxidase activity was blocked with 0.5% hydrogen peroxide (H2O2) in 
methanol for 30 minutes at room temperature (Javois, 1999).  
 
The blocking solution was discarded and drop-washed in TBS (0.05M, pH 7.2) at room 
temperature. Non-specific binding arising from the antibodies was blocked by incubation in 
2% BSA for 15 minutes at room temperature, the excess BSA was blotted off with fibre-free 
paper. The slides were incubated in primary antibody (mouse monoclonal anti-FB1; 1:100) 
overnight (12-14hrs) at 4
o
C.  Thereafter, the slides were drop-washed in TBS and TBS: 
Tween-20 (TTBS). The slides were incubated in secondary antibody (rabbit anti-mouse IgG 
conjugated to HRP; 1:100) and then washed as before. The excess TTBS was blotted off with 
fibre-free paper and stained with DAB (reconstituted according to manufacturer‟s (BioRad) 
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instructions) for 5-10 minutes in the dark constantly monitoring the colour change to avoid 
over-staining. The unbound DAB was drop-washed in deionised water and the slides were 
stained with Mayer‟s haematoxylin for 3-5 minutes. The slides were blued in hot water 
(60
o
C) and coverslipped using DPX. These slides were then analysed using the OlympusIX51 
microscope with the analysis LS software. For immunolocalisation of caspase 3 and Fas the 
same procedure was followed with the primary antibodies corresponding to caspase 3 and 
Fas. 
 
5.2.2.5 Analysis of placental DNA integrity (Hoechst stain) 
The formalin-fixed placental tissues were stained with Hoechst using the method of Farré et 
al. with minor modifications (Farré et al., 2002). Briefly, 5m placental tissue sections were 
dewaxed and permeabilised with 0.5% TritonX-100 in 0.5% sodium citrate for 8 minutes at 
RT. The cells were stained with Hoechst 33258 (Appendix D2) for 1 hour and then rinsed 
with deionised water. Sections were then mounted with DPX and viewed with a fluorescent 
microscope (Olympus IX51) at the absorption wavelength of 334nm and emission 
wavelength of 365 nm. Images were captured using the analysis LS software ensuring that 
fluorescence intensity remained constant. 
 
5.2.2.6 Analysis of lipid peroxidation in placental tissue 
Tissue (50mg) was homogenised in 500µl of 0.2%H3PO4 and centrifuged at 1491rpm. Equal 
amounts (500µl) of supernatant and 2% H3PO4 were added in a glass tube. Thereafter, the 






5.3      RESULTS 
 
Morphological analysis 
Placental tissue was analysed for morphological changes using H&E (Figure 5.2&5.3). All 
the cells that form part of a normal placenta were visualised including mesenchymal cell, 
syncytiotrophoblasts and endothelial cells. Both normotensive and preeclamptic placentas 
displayed a thinner and irregular syncytium due to the increase in number of capillaries in 
contact with the syncytial layer.  
 
Figure 5.2: Normotensive placental villi showing numerous blood vessels (V) in close 
proximity to the syncytiotrophoblastic cell layer (S), the presence of  mesenchymal cells (M) 
and erythrocytes (R) within the intervillous space (IVS) and in some capillaries [H&E] 
(600x). 
 
Another notable feature was the presence of numerous syncytial knots and nuclear aggregates 
predominantly in preeclamptic placentas compared to their normotensive counterparts 
(Figure 5.2, 5.3).  There was a high number of syncytial knots and other placental aggregates 










Figure 5.3:Preeclamptic placental villi showing a highly vascularised mesenchyme with 
numerous blood vessels (V), fusion of the syncytiotrophoblastic cell layer (S) with capillaries 
is also evident. Cytotrophoblasts (CT) visualised within the mesenchyme, numerous syncytial 
knots (SK) and nuclear aggregates (N) and erythrocytes (R) within the intervillous space 
(IVS) and in some capillaries [H&E] (600x). 
 
Immunolocalisation of FB1 in placental tissue 
The presence of FB1 within the placental tissue was analysed using IHC (Figure 5.4& 5.5). 
Fumonisin B1 was immunolocalised predominantly within the syncytial cell layer of 
preeclamptic samples compared to normotensive samples and also in the endothelial cells. In 
addition, FB1 was also present in the syncytial knots of both groups studied. However, an 
interesting feature was the presence of FB1 in preeclamptic cytotrophoblasts only and not in 
















Figure 5.4:Mature normotensive placental villi probed for the presence of FB1. Fumonisin B1 
was immunolocalised within the syncytial layer (S) and endothelial cells (E). However there 
was no FB1 within the cytotrophoblasts (CT) (400x). 
 
 
Figure 5.5: Placental villi from preeclamptic (B) samples showing positivity for FB1 (Brown 
staining). Fumonisin B1 was present within the syncytiotrophoblastic cells (S), endothelial 
cells (E) whose basement membrane has fused with the syncytial layer. Fumonisin B1 was 
also present within the cytotrophoblastic cells (CT) of preeclamptic placenta and not the 















Analysis of apoptotic markers in placental tissue 
Fas and caspase 3 were the markers localised in the placental tissue. Both Fas and caspase 3 
were expressed at greater intensity in preeclamptic placentas (Figure 5.6 &5.7). In addition to 
syncytiotrophoblast, syncytial knots also expressed Fas in preeclamptic tissue. Caspase 3 was 
expressed in mesenchymal cells, syncytiotrophoblasts and endothelial cells of preeclamptics 
while only the endothelial cells and the syncytiotrophoblasts expressed caspase 3 in 
normotensives (Figure 5.7). 
 
 
Figure 5.6: Normotensive (A) and preeclamptic (B) placental villi showing the presence of 














Figure 5.7: Mature normotensive (A) and preeclamptic (B) villi showing positive staining for 
caspase 3 (Brown staining). Caspase 3 was immunolocalised apically in the cytoplasm of 
syncytiotrophoblasts (S), endothelium (E) and the mesenchyme (M) (400x). 
 
Fragmented DNA was higher in preeclamptic samples compared to normotensive 
counterparts. The syncytial layer, endothelial and mesenchymal cells showed higher levels of 












Figure 5.8: Normotensive (A) and preeclamptic (B) villi  showing uniform staining in the 
normotensive sample and an increased number of cells with condensed chromatin (arrow) 
predominantly within the syncytium (S) and also the endothelial cells (E) and syncytial knots 
(SK) of preeclamptic sample(B) (400x). 
 
Placental MDA levels as an indicator of lipid peroxidation 
Malondialdehyde (MDA) concentrations are used as indicators of lipid peroxidation in cells. 
The levels of MDA were significantly higher in preeclamptic placental samples compared to 
normotensive placentas (Figure 5.9). The mean MDA concentration in preeclamptic placentas 
















































Figure 5.9:Graphical representation of lipid peroxide levels in normotensive and 
preeclamptic placental tissue samples. The lipid peroxides (MDA) were significantly higher 
(p0.0001) in preeclamptic placental tissues compared to the normotensive counterparts. 
Unpaired t-test with Welch‟s correction. 
 
5.4     DISCUSSION 
Morphological analysis of placental samples using H & E revealed fusion between the 
basement membrane of endothelial cells with that of the syncytium. This feature is common 
in the last weeks (third trimester) of gestation and is thought to reduce the diffusion barrier 
and facilitate exchange of substances between maternal and foetal circulation (Figures 5.2 & 
5.3). The nuclei are usually absent or very sparsely distributed in these areas, a feature that 
was observed in this study (Huppertz, 2008). This study also demonstrated the presence of 
nuclear aggregates in preeclamptic placental samples compared to normotensive counterparts 
(Figures 5.2 &5.3). 
 
These nuclear aggregates have been previously characterised into three broad categories 




of immature nuclei and are usually present in the first trimester of pregnancy where they act 
as precursors of newly formed villi. Fusion of the sprouts results in syncytial bridges which 
are thought to give support to the villous tree while aggregates of degenerating nuclei 
protruding from the villous surface are called syncytial knots (Jones and Fox, 1977). Boyd 
and Hamilton were the first to describe the presence of stromal trophoblastic buds which are 
found within the villi of most placentas possessing cytotrophoblasts on their periphery 
surrounding a central core of syncytium (Boyd and Hamilton, 1964).  
 
Several studies have reported a significant increase in the frequency of syncytial knots in 
preeclamptic pregnancies compared to their normotensive counterparts. As previously 
described, these knots are aggregated nuclei of degenerating syncytial cells. Thus an increase 
in the number of syncytial knots may indicate a high level of syncytiotrophoblast apoptosis 
(Heazell et al., 2007, Kadyrov et al., 2006, Huppertz et al., 1998, Mayhew et al., 1999). 
Indeed, this study showed increased Fas and caspase 3 expression in preeclamptics compared 
to their normotensive counterparts thus confirming apoptosis in these cells. Austgulen et al. 
also showed an increased in apoptosis in the syncytial layer of preeclamptic placentas 
compared to the control groups (Austgulen et al., 2004).  
 
Fumonisin B1 was also immunolocalised within the placental tissue using 
immunohistochemistry specifically within the syncytiotrophoblastic cell layer (predominant), 
endothelial cells, syncytial knots and mesenchymal cells of both groups. Of particular interest 
was the presence of FB1 within the cytotrophoblasts of preeclamptic villi and not in 
normotensive villi. Fumonisin B1 has been previously demonstrated to interact with proteins 
by binding to either the thiol or amino groups on the amino acid residues (Seefelder et al., 
2003b). One such amino acid is lysine, which contains alpha () and epsilon () amino 
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groups. The alpha amino group is involved in peptide bond formation whilst the epsilon 
confers structural characteristics to lysine. The amino group on lysine would therefore 
interact with tricarballylic acid moieties on FB1.  The placenta is a highly vascularised tissue 
and thus would be very rich in extracellular matrix components that form the basement 
membrane. Various types of collagen have been identified in the placental basement 
membrane. This collagen is very rich in lysine and thus would also be able to interact with 
FB1 through a similar mechanism described above. For this reason FB1 was predominantly 
localised on the endothelial layer and syncytium possibly in their basement membranes.  
 
Other lysine-rich proteins include albumin and histones. All of these proteins therefore are 
potential targets for FB1.  This study has however not identified the amino acids or proteins 
involved in the interaction with FB1 and therefore future investigations will aim to investigate 
the identity of the amino acids binding to FB1 using mass spectrometry. This will confirm the 
types of interactions between FB1 and macromolecules in biological samples. The 
intracellular localisation of FB1 in tissue was also previously demonstrated both in vivo and in 
vitro thus indicating the ability of FB1 to enter cells. The mechanism postulated is through its 
terminal amino group which would allow FB1 to be recognised by protein transporters on the 
plasma membrane (Myburg et al., 2009, Cawood et al., 1994).  
 
The syncytial layer forms a barrier between foetal and maternal blood and therefore if this 
layer is compromised in any way could result in maternally derived toxins gaining entry into 
the foetal blood due to the close proximity of foetal blood vessels to the syncytial layer. This 
study has demonstrated that FB1is able to gain entry into the syncytiotrophoblasts raising a 
question as to whether it is involved in the increased shedding of trophoblasts observed in 
preeclamptic samples. As a result of this compromised lifespan of syncytial cells, the 
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cytotrophoblastic cells needed to regenerate this layer are recruited to the area and need to 
differentiate into syncytial cells. Therefore the presence of FB1 in the cytotrophoblasts of 
preeclamptic but not normotensive women warrants further investigation as it may affect the 
biological and functional ability of these cells. The importance of these cells in the invasion 
of spiral arteries has been previously demonstrated (Zhou et al., 1997). The primary reason 
for the failure to invade spiral arteries is due to the inability of cytotrophoblasts to express 
several adhesion molecules such as integrin and cadherin important for this function (Zhou et 
al., 1997, Khong et al., 1986). The presence of FB1 in these cells may induce production of 
reactive oxygen species through its interactions with molecules such as tumour necrosis 
factor (TNF-). Only a few studies have been conducted on the presence of FB1 in the 
placental tissue and currently only one study has shown a similar pattern of binding in 
placental tissues as the one observed in this study (Coumi, 2000; unpublished data). The 
presence of FB1 in these cells may also result in a disruption of sphingolipid molecules 
including sphinganine and sphingosine which are known inducers of apoptosis. This study 
demonstrated very high levels of apoptosis in preeclamptic tissues compared to normotensive 
tissues through analysis of key apoptotic markers (caspase 3, Hoechst, Fas). This finding is in 
agreement with various studies which also demonstrated a similar result (DiFederico et al., 
1999, Allaire et al., 2000, Ishihara et al., 2002, Genbacev et al., 1999, Goswami et al., 2006).   
 
In addition, lipid peroxidation was significantly higher in preelamptic compared to 
normotensive samples. This was also demonstrated in the serum samples (chapter 3) where 
lipid peroxidation was higher in preeclamptics compared to normotensives. Pregnancy is 
associated with high levels of oxidative stress due to the increased energy demand from the 
developing placenta and the resultant increase in mitochondrial activity which are the primary 
source of ROS. Oxidative stress is exaggerated in preeclamptic pregnancies and has been 
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attributed to the imbalance in antioxidants (Myatt and Cui, 2004, Serdar et al., 2002).  
Although the levels of MDA were remarkably high in preeclamptic samples, it is important to 
mention that the TBA used in the measurement of MDA is not specific for MDA only but 
cross-reactivity with other molecules such as sugars, urea, alkanals and proteins has been 
demonstrated and therefore extreme caution should be exercised when making conclusions 
from the TBARS assay. Albumin has been shown to translocate in and out of the blood into 
various tissues and analysis of its oxidation status would therefore give a better indication of 
the overall oxidative status in the body (Terawaki et al., 2004). In addition to oxidised 
albumin, MDA is known to interact with DNA and protein forming adducts and the use of 
HPLC and mass spectrometry would provide invaluable information on these adducts and 
provide a more sensitive indicator of lipid peroxidation and overall oxidative stress in vivo. 
 
The higher levels of apoptosis observed in preeclamptic placentas may be due to various 
factors including the increased concentrations of sphingoid bases (sphinganine and 
sphingosine) and increased lipid peroxidation. The previous chapter (table 4.1 and Figures 
4.6&4.7) in the current study demonstrated significantly high levels of Sa and So in 
preeclamptic sera compared to normotensive sera. Sphinganine is a known pro-apoptotic 
molecule and thus its presence at such high levels indicates the potential role it plays in the 
induction of apoptosis in trophoblasts. It is therefore reasonable to postulate that due to the 
increase is sphinganine, the trophoblasts are stimulated to undergo apoptosis whilst in 
normotensive samples the low levels of sphingoid bases may not be sufficient to induce 
apoptosis to such a high degree. The Hoechst stain demonstrated high levels of cells 
undergoing apoptosis in preeclamptic samples compared to normotensives. Fumonisin B1 is a 
known inducer of apoptosis through various mechanisms (Ciacci-Zanella and Jones, 1999, 
Seefelder et al., 2003a). The increase in sphinganine being one of them, in addition FB1 has 
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been shown to use the death receptor pathway to induce apoptosis and through up-regulation 
of caspase 3 and all of these were demonstrated in this study (Seefelder et al., 2003a).  
 
5.5     CONCLUSION 
This study showed the presence of FB1in placental tissue and its potential risk to the foetus.  
There were also high levels of apoptosis and lipid peroxidation in preeclamptic placental 
samples which may indicate aberrant physiological processes such as a decreased antioxidant 
response. Fumonisin B1 is postulated to induce apoptosis in the placental through the death 
receptor pathway (Fas), induction of caspase 3 activity, sphingolipid disruption and DNA 
fragmentation (Hoechst). The use of MDA as an indicator of apoptosis has been brought 
under scrutiny and therefore measurements of oxidised albumin, DNA and protein adducts 
may have strengthened the findings in this study. It is unlikely that FB1 is solely responsible 
for the exaggerated apoptosis observed in preeclampsia. However, the evidence presented in 















This study demonstrated the presence of FB1 and its associated metabolites in the blood and 
placenta of normotensive and preeclamptic women. The high levels of FB1 observed in 
preeclamptic samples were attributed to the consumption of dietary staples and aberrant 
physiological processes including proteinuria and the conjugation to body proteins. Although 
it is tempting to conclude that FB1 is the cause of all these observations, it is important to 
note that co-contamination of maize by fungi may result in multi-mycotoxin exposure thus 
indicating possible interactions that may have led to the observations in this study. To date no 
study has surveyed the different mycotoxins commonly known to colonise maize in humans 
and only one has probed for the presence of FB1 in pregnant women. Other mycotoxins may 
be involved in the toxicity of FB1 and therefore need to be determined in this population 
group to not only protect the mothers but also the developing foetus. 
 
This study not only demonstrated the presence of FB1 but also measured the sphingolipid 
changes associated with its toxicity. It is the first study to measure the levels of sphingoid 
bases, sphinganine and sphingosine in the blood of pregnant women.  The increase in 
apoptosis and lipid peroxides in preeclamptic samples may be attributed to the observed 
elevation in sphinganine and sphingosine. 
 
The samples used in the study were obtained from a single hospital in KZN which may not be 
a representative sample of the situation in the whole province. A comparison between 
pregnant women from rural and urban hospitals would have strengthened the hypothesis that 
rural communities were at a higher risk of FB1 toxicity than their urban counterparts. A 
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dietary questionnaire should have been included to ascertain how often the women consumed 
maize and maize-based products. 
 
Although this study showed the interaction of FB1 with albumin, other proteins like collagen 
may also be involved especially in sequestering FB1 in tissues like the placenta. Therefore the 
findings in this study highlighted the importance of food screening and also education around 
good agricultural practices. A recent intervention study in the Eastern Cape Province on the 
prevention of consumption of mouldy maize has provided some hope with regard to training 
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Appendix A: Information given to participants and informed consent document 
 




Study title: The effects of fumonisin B1 in pre-eclampsia. 
 
Greeting: Dear participant 
 
Introduction: 
I am Miss Metse Serumula, a researcher working with Professors A Chuturgoon and J 
Moodley. We are doing a research project studying the effects of a toxin called fumonisin B1, 
present in maize and maize meal, on placental DNA.  Research is a process done in order to 
learn answer to question. Moulds are commonly known as fungi. These fungi sometimes 
produce poisonous substance called mycotoxins and fumonisin B1 is a poisonous substance 
produced by fungi which are commonly found on maize (mealie) or mealie-based products. It 
has been shown in previous studies that people with high blood pressure in pregnancy had 
high levels of these toxins (fumonisin B1) in their blood. You have been informed that you 
have high blood pressure in pregnancy (pre-eclampsia). We would like to invite you to 
participate in our study. 
What does participation mean? 
This means that if you agree to participate, we will obtain a sample of your blood (15ml), a 
tablespoon full. The taking of blood samples will be done at the same time as the other 
routine bloods are taken so that no further discomfort is caused to you. In addition, once you 
have delivered, we would like to take four blocks of tissue, the size of a pigeon’s egg 
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(2cmx2cm) from the afterbirth (placenta). Taking of blood samples and afterbirth tissue will 
not have any effect on you or your baby. Normally the “afterbirth” is destroyed. 
 
What is involved in the study?  
After collection of the bloods and afterbirth tissue samples, bloods will be separated into 
blood cells (lymphocytes) and blood fluid (plasma/serum) and stored in a freezer (-70
0
C). 
One block of afterbirth tissue (2cm x2cm, the size of a pigeon‟s egg) will be stored in the 
freezer (-70
0
C) and 3 afterbirth tissues immersed in formalin will be stored in a cupboard (at 
25 
0
C. The following methods will be used in order to help us understand the role of 
mycotoxins.  The blood will be analysed/ tested using flow cytometry and high perfomance 
liquid chromatography while the tissue samples will be tested using immunohistochemistry, 
high performance liquid chromatography, Hoechst and JC-1 staining.  
 
Benefits of being in the study. The study will not have any direct impact on you or your 
treatment but may help in providing further information given to pregnant women with high 
blood pressure or those women who are likely to develop high blood pressure in pregnancy. 
 
Participation is voluntary, and if you do not decide to participate in this study, your 
treatment will not be different in any way. The doctors will manage you in the same way that 
they manage patients with your condition. You may discontinue your participation in the 
study and this will also not affect your treatment in any way.  
 
Confidentiality: Efforts will be made to keep personal information confidential.  Absolute 
confidentiality cannot be guaranteed. We will be using the results of the study for 
publication; however no names of participants will be used. In addition note that I am doing 
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this research to obtain a higher degree and thus it is part of my studies to become a scientist/-
experienced researcher. Personal information may be disclosed if required by law. Certain 
Organizations such as Research ethics committee may inspect and/or copy your research 
records for quality assurance and data analysis.   
 
For further information please contact the following people all located in the Nelson R. 
Mandela School of Medicine: 
1. Miss Metse Serumula (Principal investigation), Room 547D, Division of Medical 
Biochemistry (031 260 4597). I will be willing to answer your queries in the language 
you are most comfortable with. 
2. Professor Anil Chuturgoon (supervisor), Mycotoxin Research Unit-Doris Duke 
Medical Research Institute (031 260 4404) 
3. Professor J.  Moodley (co-supervisor), Room 108A, Obstetrics and Gynaecology( 031 
260 4250),  
 
4. Contact details of REC administrator and chair – for reporting of complaints / 
problems. 
      Mrs Cheryl Borresen Room 211 MRC building (031 260 4495) 
 
 





Consent to Participate in Research 
 
You have been asked to participate in a research study. 
 
You have been informed about the study by …Metse Serumula……………………. . 
 
Where applicable: You have been informed about any available compensation or medical 
treatment if injury occurs as a result of study-related procedures; 
  
You may contact Metse Serumula…………………. at 260 4597………… any time if you 




You may contact the Medical Research Office at the Nelson R Mandela School of Medicine 
at  
031-260 4604 if you have questions about your rights as a research subject. 
 
Your participation in this research is voluntary, and you will not be penalized or lose benefits 
if you refuse to participate or decide to stop. 
 
If you agree to participate, you will be given a signed copy of this document and the 
participant information sheet which is a written summary of the research. 
 
The research study, including the above information, has been described to me orally. I 
understand what my involvement in the study means and I voluntarily agree to participate. 
 
 
_________________               ______________ 
Signature of Participant                            Date 
 
 
____________________                  __________________ 
Signature of Witness                                Date 
(Where applicable)      
 
 
____________________                   _________________ 





Zulu translation of the informed consent document 
 
 




Isihloko socwaningo: Effects of fumonisin B1 in pre-eclampsia 
 





Ngingu Nkosazane Metse Serumula, umncwaningi osebenzisana no Profesa Chuturgoon 
kanye no Moodley. Senza ucwaningo ngemiphumela yobuthi obubizwa nge fumonisin B1, 
obutholakala embileni nase mpushini. Ucwaningo uhlelo olwenziwa ukuze kutholakale 
impendulo emubuzweni othile. Uboyana obutholakala entweni eyonakele noma ebolile 
kwaziwa njengesikhunta. Kwesinye isikhathi lesisikhunta siqhiqiza ubuthi obuthile okubizwa 
nge mycotoxins kanye ne fumonisin B1 okuwubuthi obuqhiqizwa yisikhunta esitholakala 
embileni noma ekudleni okwenziwe ngombila. Kolunye ucwaningo oselwenziwa kubonakele 
ukuthi abantu besifazane abane BP (high blood pressure) ephezulu ngesikhathi bekhulelwe 
babenezinga eliphezulu lalobubuthi (fumonisin B1) egazini labo. Sewazisiwe ukuthi njengoba 
ukhulelwe une BP ephezulu. Sifisa ke ukukumema ukuba ungenele lolucwaningo lwethu. 
 
Kusho ukuthini ukubayingxenye yalolucwaningo? 
Lokhu kusho ukuthi uma uvuma ukuba yingxenye yalolucwaningo, siyothatha kuwe 
isampula legazi elilinganiselwa ku (15ml), okungaba yigazi elingange sipunu sokudla 
esigcwele. Konke ukuthathwa kwegazi kuyokwenziwa ngesikhathi esifanayo noma esisodwa 
ukuze ungalokhu uzwa ubuhlungu. Ukwengeza kulokhu, ngemuva kokubeletha, sifisa 
ukuthatha izicubu ezine, ezilingana namaqanda ejuba (2cmx2cm) esiyozithatha kumzanyana 
(placenta) ophuma ngemuva kokubeletha. Ukuthathwa kwegazi nezicubu kumzanyana 
angeke kukuphazamisa wena kanye nomntwana wakho.  Ngokwenjwayelo “umzanyana” 
uyalahlwa. 
 
Yini eyokwenzeka kulolucwaningo:  
Ngemuva kokuthatha amagazi nezicubu kumzanyana, amagazi ayohlukaniswa bese egcinwa 
endaweni eno ayisi. Isicubu esisisodwa esilingana neqanda lejuba siyogcinwa esiqandisini 
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esibanda ngendlela efanayo nokubekwe kuyo igazi bese kuthi izicubu ezintathu ziyocwiliswa 
oketshezini olubizwa nge formalin zigcinwe ekhabetheni. Lokhu kuyokwenziwa ukuze 
siqonde ukuthi ubuthi besikhunta budlayiphi indima. Igazi lakho kanye nezicubu ezithathwe 
kumzanyana wakho kuyocutshungulwa besekuhlolwa.  
 
Inzuzo yokuba kulolucwaningo. Lolucwaningo alunakuku phazamisa noma luphazamise 
uhlelo lokunakekelwa noma ukwelashwa kwakho kepha lungasisiza ukuba sithole ulwazi 
kabanzi ngabantu besifazane ababa ne BP ephezulu ngesikhathi bekhulelwe noma kulabo 
besifazane okunokwenzeka babe ne BP ephezulu ngesikhathi bekhulelwe. 
 
Ukuba kulolucwaningo kuwubuvolontiya, uma futhi uthatha isinqumo sokungabi 
yingxenye yalolucwaningo ukunakekeleka kwakho akunakuphazamiseka. Odokotela 
bayokunakekela ngendlela efanayo nabanakekela ngayo iziguli ezisesimweni esifana 
nesakho. Ungaphuma futhi kulolucwaningo noma ingasiphi isikhathi lokhu 
akunakuphazamisa  ukwelashwa kwakho. 
 
Imfihlo: Kuyokwenziwa imizamo yokugcina imininingwane yakho iyimfihlo. 
Akunakuqinisekiswa imfihlo ephelele. Imiphumela yalolucwaningo iyosetshenziswa 
emibhalweni eyoshicilelwa, kepha angeke kusetshenziswe magama abantu ababeyingxenye 
yalolucwaningo. Ngaphezu kwalokhu ngiyafisa ukuba wazi ukuthi ngenza lolucwaningo 
ukuze ngithole iziqu zemfundo ephezulu, kuyingxenye yokufunda kwami ukuba ngibe 
ngumcwaningi osezingeni eliphezulu. Iminingwane yakho ingadalulwa uma lokhu kufunwa 
ngumthetho. Ezinye izinhlangano njengekomiti locwaningo lase Nyuvesi (Research ethics 
committee) zingabheka imibhalo yakho yalolucwaningo noma futhi zikopishe imininingwane 
yakho ukuze ziqinisekise ukuthi yonke into yenzeka ngendlela efanele.   
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Uma ufuna olunye ulwazi uyacelwa ukuba uxhumane nalababantu bonke abatholakala 
esikoleni sokufundela odokotela i Nelson R. Mandela School of Medicine: 
5. Unkosazane Metse Serumula (umcwaningi omkhulu), Room 547D, kuMnyango we 
Medical Biochemistry (031 260 4597). Ngiyozama ukuphendula imibuzo yakho 
ngolimi ofisa ukuba ngiyiphendule ngalo. 
6. Profesa Anil Chuturgoon (ophethe lolucwaningo), Mycotoxin Research Unit-Doris 
Duke Medical Research Institute (031 260 4404) 
7. Profesa J.  Moodley (obambisene nophethe), Room 108A, Obstetrics and 
Gynaecology( 031 260 4250) 
8. Imininingwane yophethe ikomiti locwaningo – uma ufisa ukubeka izikhalo zakho 
noma izinkinga zakho ngalolucwaningo. Mrs Cheryl Borresen Room 211 MRC 
building (031 260 4495) 
 
INGXENYE YESIHLANU: IFOMU ELIKUNIKA ULWAZI NGALOLUCWANINGO 
NOKUYIFOMU LESIVUMELWANIO NGALOLUCWANINGO :  
UMBHALO WESIVUMELWANO 
 
Imvume yokuba yingxenye kulolucwaningo 
 
Uceliwe ukuba ube yingxenye yalolucwaningo. 
 
Sewazisiwe ngalolucwaningo ngu … ……………………. . 
 
Lapho kufanele khona: wazisiwe ngesinxephezelo noma ukwelashwa uma kwenzeka ulimala 
ngenxa yalolucwaningo; 
  
Ungaxhumana no Metse Serumula……. ku  260 4597………… noma ingasiphi isikhathi 
uma unemibuzo ngalolucwaningo noma uma ulimala ngenxa yalolucwaningo. 
Uma unemibuzo ngamalungelo akho njengomuntu okulolucwaningo ungaxhumana ne 
Medical Research Office esikoleni sodokotela eNelson R. Mandela School of  




Ukuba kulolucwaningo kuwukuthanda kwakho, angeke ujeziswe noma ulahlekelwe 
ngamalungelo akho uma unqaba ukuba kulolucwaningo noma uthatha isinqumo sokuphuma 
kulolucwaningo noma ingasiphi isikhathi. 
 
Uma uvuma ukuba kulolucwaningo, uyonikezwa ikhophi yalelifomu esayiniwe kanye 
nefomu elinika ulwazi ngalolucwaningo okuyifomu elinolwazi olufingqiwe ngalolucwaningo. 
 
Ngichazelwe ngomlomo ngalolucwaningo kanye nangalolulwazi olungenhla.  Ngiyaqonda 
ukuthi kusho ukuthini ukuba kwami kulolucwaningo futhi ngiyazikhethela ngaphandle 
kokuphoqwa ukuthi ngibe  kulolucwaningo. 
 
_________________               ______________ 
Isiginesha yevolontiya                   Usuku 
 
_________________             ______________   
Isiginesha kafakazi                        Usuku   
(Uma kufanele) 
 
_________________  ______________ 
Isiginesha katolika                     Usuku 
(Uma kufanele)           
 
Appendix B:  Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
and western blotting reagents 
 
1. Bovine serum albumin (BSA) serial dilutions 
 
Table A1 BSA serial dilutions used in the bicinchoninic acid assay 
 
Concentration  Volume of sample Volume of storage buffer 
0mg/ml 0l 1000l 
0.2mg/ml 200l 800l 
0.4mgml 400l 600l 
0.6mg/ml 600l 400l 
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0.8mg/ml 800l 200l 
1.0mgml 1000l 0l 
 
The volume of sample required to make a specific BSA concentration was calculated using 
the following formula 
 C1V1 = C2V2 
V1 = C2V2/C1 
     =  0.2mg/ml x 1ml / 1mg/ml 
     = 0.2ml = 200l of BSA Stock + 800l of storage buffer to make up 1ml (1000l) 
 
1.1 Bicinchoninic acid (BCA) working solution 
4µl of CUIISO4 was combined with 198µl BCA per well. 
1.2 Standard curve of BSA standards 
 
Figure A1.  Standard curve of BSA serial dilutions for protein quantification. 
The equation: y =0.9641 x0.016 was then used to calculate protein concentrations in the 
sample 
 
2. Storage buffer  
 
0.5mM Na2-EDTA 
M1V1 = M2V2 
100. x = 0.5mMx100ml 


































0.1M KH2PO4 (pH7.4)* 
N = C x V 
= 0.1 x 0.1 
= 0.01 moles 
Mass = n x Molar mass 
0.01x 136.04g/mol 
1.3604g 
Combine all ingredients and make it up to 100ml with deionised water (Adjust pH to 7.5) 




1* x = 0.0001*0.1 
=10l 
0.25 M Sucrose 
N = C x V 
= 0.25M x 0.1l 
= 0.025 moles 
Mass = n x molar mass 
= 0.025 x 342.3g/mol 
= 8.5575g 
Combine all other ingredients except KH2PO4 and use it to adjust volume to 100ml. 
 
3. Resolving and stacking gel preparations 
3.1 Table A2 Resolving gel preparation (0.375M Tris, pH 8.8) 
 
 12% 10% 
Deionised water 3.35ml 3.95 ml 
0.5M Tris-HCL<pH 8.8 2.5ml 2.5 ml 
10% (w/v) SDS stock (store at RT) 100l 100l 
Acrylamide/Bis (30% stock) degas for 
15 min at RT) 
4.0ml 3.35ml 





Tetramethylethylenediamine(TEMED) 5l 5l 
Total monomer* 10ml 10ml 
 
3.2 Table A3 Stacking gel preparation 4% gel, 0.125M Tris, pH 6.8 
 
Deionised water 6.1ml 
0.5M Tris-HCL, pH 6.8 2.5ml 
10% (w/v) SDS 100l 
Acrylamide/bis (30% stock) 1.33ml 




Total monomer* 10ml 
 
*Combine all reagents in the monomer solution except the TEMED and APS and degas 
under vacuum for 15minutes. Then add the APS and TEMED to initiate polymerization. 
Swirl gently to mix. 
 
3.3 Table A4 Sample buffer (SDS reducing buffer) store at room temperature 
 
Deionised water 3.8ml 
0.5M Tris-HCL, pH 6.8 1.0ml 
Glycerol 0.8ml 
10% (w/v) SDS 1.6ml 
2-mercaptoethanol 0.4ml 




4. Gel staining and destaining solution 
4.1 Coomasie brilliant blue staining stock solution (1% comassie brilliant blue R-
250) 
Coomassie brilliant blue (CB) R-250  1g 
Deionised water (DH2O)   100ml 
 
4.1.1 Staining solution (0.125 CB-R250; 50% Methanol; 10% Acetic acid) 
Coomassie brilliant blue R-250 (from stock)  62.5ml  
Methanol       250ml 
Acetic acid      50ml 
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DH2O to 500ml 
 
4.2 Destaining solution 1 (50% methanol, 10% acetic acid)  
Methanol  500ml 
Acetic acid  100ml 
DH2O to 1 litre 
 
4.3 Destaining solution 2 (7% Methanol, 5%acetic acid) 
Methanol  70ml 
Acetic acid  50ml  
DH2O to 1 litre 
 
5. 5X electrode (running) buffer, pH 8.3 
Tris base 9g 15g/l 
Glycine 43.2g 72g/l 
SDS 3g 5g/l 
To 600ml with DH2O 
Store at 4
0
C. Warm to room temperature if precipitation occurs. 
Dilute 60ml of 5X stock with 240ml of DH2O for electrophoretic 
run. 
 
6. Transfer buffer 
192mM Glycine  14.4g 
25mM Tris   3.03g 
Methanol   100ml 




7. 0.05%Tris buffered Saline with Tween-20 (0.05%) (pH 7.5) [TTBS] 
20mM Tris  3g 
150mM NaCl  8g 
KCl   0.2g 
0.05% Tween 20 5ml 
Dissolve all ingredients in 1litre of DH2O then add 10%Tween 20 to make 0.05% TTBS 
Appendix C:  High performance liquid chromatography (HPLC) reagents 
 
1. O-pthaldialdehyde (OPA) 
Dissolve 20mg of OPA in 600l of methanol  
5ml of 0.1M di-sodium tetraborate (pH 10.5)  
50l of 2-mercaptoethanol and store in the dark at RT. 
 
Appendix D: Placental tissue processing and staining solutions 
1:  Haematoxylin and Eosin (H & E) staining solutions 
1.1 Mayer’s Haematoxylin solution 
Potassium or ammonium (alum)   50g 
Haematoxylin  (Mayer‟s)    1g 
Sodium iodate     0.2g 
Citric acid     1g 
Distilled water 1Litre 
Stir to dissolve the chemicals in the order listed above 




1.2 Eosin-Phloxine B solution  
Eosin Stock solution 
Eosin Y   1g 
Distilled water 100ml 
Mix to dissolve and store at room temperature 
 
Phloxine B stock solution 
Phloxine B  1g 
Distilled water 100ml 
Mix to dissolve 
 
Eosin-Phloxine B working solution (0.25%) 
Eosin stock solution   100ml 
Phloxine stock solution  10ml 
Ethanol (95%)    780ml 
Glacial acetic acid (concentrated) 4ml 
Combine all ingredients and store at room temperature 
 
2. Hoechst Staining solution 
Dissolve 1mg of Hoechst 33258 in 1ml deionised water and then dilute to 20g/ml 
with deionised water.  
Use the following equation for calculation volume required 
C1V1 =C2V2 
V1 =  0.02mg/ml x5ml /1mg/ml 
     = 0.1ml = 100l 
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Combine 0.1ml of Hoechst 33258 stock solution with 4.9ml of deionised water to 
make a final volume of 5ml and final concentration of 20g/ml. 
 
3.       Antigen retrieval buffer Sodium Citrate Buffer (10mM Sodium Citrate, 0.05% 
Tween     20, pH 6.0) 
 
      Tri-sodium citrate (dihydrate) --------- 2.94 g 
      Distilled water --------------------------- 1000 ml 
Mix to dissolve. Adjust pH to 6.0 with 1N HCl and then add 0.5 ml of Tween 20 and mix 
well. Store this solution at room temperature for 3 months or at 4
o
C for longer storage. 
 
 
